

---

## Author Index to Volumes 44-50

---

- Aalders JG, 44:223  
 Abdelhay E, 47:275  
 Abe T, 49:219  
 Adhvaryu SG, 48:135  
 Advani SH, 50:89; 50:109  
 Aissaoui Z, 48:209  
 Akrad M, 50:189  
 Alberts KA, 48:101  
 Alumets J, 48:225  
 Amagasaki T, 50:149  
 Angelucci D, 50:277  
 Archidiacono N, 46:1  
 Armitage JO, 47:73  
 Asou N, 47:277  
 Atkin NB, 44:229;  
     46:129; 49:281  
 Atkins L, 45:41  
 Aurias A, 45:55  
 Aventín A, 50:227  
  
 Babin P, 45:125  
 Babińska M, 49:259  
 Babonits M, 46:93  
 Babu VR, 48:83  
 Baczek NA, 45:179  
 Badia L, 45:1  
 Baer MR, 45:67  
 Baker MC, 44:229; 49:281  
 Bal S, 48:199  
 Balar DB, 48:135  
 Baldetorp B, 48:217  
 Balogh E, 44:119  
 Balsara BR, 50:89  
 Banks-Schlegel SP,  
     45:101  
 Bardi G, 49:51  
 Barrios L, 49:107  
 Bartholdi MF, 50:231  
 Bartnitzke S, 44:253;  
     46:55; 49:165; 50:161  
 Bauchinger M, 47:219;  
     48:13  
  
 Bauters F, 46:173  
 Becher R, 44:181  
 Beckett MA, 50:125  
 Belge G, 44:253  
 Bello MJ, 45:223  
 Ben-Bassat H, 49:241  
 Ben-Bassat I, 47:139,  
     48:125, 48:279  
 Benet J, 46:251  
 Beneyto M, 45:1  
 Benitez J, 44:277; 46:281  
 Benn P, 48:75  
 Bennett J, 48:131  
 Benoit Y, 45:49  
 Berg SL, 44:55  
 Berger CS, 47:95; 47:179  
 Berger R, 44:69; 44:143;  
     49:265; 50:53  
 Bergerheim USR, 49:125  
 Beris P, 44:271  
 Beris Ph, 46:157  
 Berkowicz M, 47:139;  
     48:125, 48:279  
 Bernacer M, 44:277  
 Bernstein R, 50:153  
 Berrozpe G, 50:9  
 Bertness VL, 44:47  
 Beverstock GC, 48:179  
 Bhisey AN, 50:89  
 Bigner DD, 47:141  
 Bigner SH, 47:141  
 Bignon J, 49:37  
 Biörklund A, 44:209  
 Birch JM, 45:245  
 Bixenman HA, 46:135;  
     49:137  
 Block AW, 50:171  
 Bojan F, 44:119  
 Bonfill X, 46:251  
 Boogaerts MA, 49:171  
 Bordes R, 50:227  
 Borek DA, 47:61  
  
 Borman LS, 46:231  
 Bosga-Bouwer A, 50:103  
 Bosl GJ, 50:67  
 Bouts MJ, 47:1  
 Branco P, 49:103  
 Branda RF, 46:231  
 Brandt G, 44:253  
 Briault S, 45:125  
 Bridge JA, 47:61; 49:199  
 Brinck-Johnsen T, 47:227  
 Britton V, 47:265  
 Brizard A, 45:125  
 Brøgger A, 45:85; 47:69  
 Brothman AR, 47:135;  
     49:277  
 Broun ER, 46:125  
 Brunet S, 50:227  
 Buist J, 44:217; 44:223;  
     46:75  
 Bullerdiel J, 44:253;  
     46:55; 49:165; 50:161  
 Bülow S, 50:139  
 Burgio GR, 45:137  
 Burvall K, 48:183  
 Butti G, 45:237  
 Byrd R, 49:277  
  
 Caballin MR, 44:193,  
     50:9  
 Caballín MR, 46:251,  
     49:107, 49:133  
 Calabrese G, 50:277  
 Calasanz MJ, 48:133  
 Calderone C, 44:61  
 Campagnoli E, 45:137  
 Campbell EW, 48:89  
 Caracino A, 50:277  
 Carter J, 48:255  
 Casalone R, 45:237;  
     45:269; 45:273  
 Cascinelli N, 44:61  
 Caselitz J, 50:161

- Cassiman J-J, 45:217;  
 49:87; 49:171  
 Castedo SMMJ, 44:223;  
 48:143; 49:103  
 Castel V, 45:1  
 Cavenee WK, 49:15  
 Cedrone E, 46:271;  
 50:199  
 Celli P, 48:39  
 Cerny JC, 48:83  
 Cervenka J, 50:265  
 Chadduck WM, 47:89;  
 47:101  
 Chaganti RSK, 50:67  
 Chakrabarti S, 48:23  
 Challinor PR, 45:261  
 Champlin R, 49:177  
 Chaparro M, 50:153  
 Chase CL, 46:21; 50:119  
 Chen D, 48:89  
 Chen SJ, 44:69; 44:143  
 Chen TR, 48:139  
 Chen Y-C, 47:29  
 Chen Z, 44:143  
 Chisesi T, 48:39  
 Chlecq C, 49:37  
 Choi BH, 45:207; 50:153  
 Chu D, 49:235  
 Chuang S-M, 49:31  
 Cianchetti E, 50:277  
 Cigudosa JC, 48:133  
 Coll MD, 44:193, 49:133  
 Collin F, 48:281  
 Collins VP, 49:125  
 Collyn-d'Hooghe M,  
 48:209  
 Colombies P, 44:275  
 Columbano-Green LM,  
 48:255  
 Cordova LM, 45:179  
 Cosson A, 46:173  
 Cossu L, 47:273  
 Couturier J, 44:243; 45:55  
 Couzigou P, 49:249  
 Cowan JM, 50:125  
 Cram LS, 50:231  
 Creasy M, 45:261  
 Crossen PE, 48:255  
 Curless R, 44:263  
 Curtis D, 45:93  
  
 Dadabhoy KD, 50:89  
 Dadley B, 50:171  
 Daeschner CW III, 50:169  
 Daghistani D, 44:263  
 Dahl N, 46:115  
 Dahlenfors R, 44:1; 46:35  
 Dal Cin P, 45:49  
 Dale BM, 44:99  
  
 D'Alessandro E, 45:231  
 Dallorso S, 47:41  
 Dalton A, 45:93  
 Dam A, 44:217  
 Darnaude MT, 45:35  
 Dastugue N, 44:275  
 Davies H, 47:249  
 de Andrés L, 50:227  
 DeBauche DM, 46:261  
 Dębiec-Rychter M, 46:29  
 Decker H-JH, 46:135  
 De Cremoux H, 49:37  
 Defferrari R, 48:35  
 Dejana A, 48:35  
 de Jong B, 44:217;  
 44:223; 46:75;  
 48:143; 50:103  
 de la Chapelle A, 48:1  
 Delannoy A, 48:49  
 Delattre O, 44:107; 45:55  
 Delfau MH, 48:209  
 Delicado A, 45:35  
 Della Porta G, 44:61  
 Del Porto G, 45:231;  
 48:237  
 De Miguel A, 44:193  
 Deminatti M, 46:173;  
 48:209  
 Demuynck H, 49:171  
 De Potter C, 45:49  
 Derré J, 44:69; 50:53  
 Desablens B, 48:209  
 de Torres ML, 45:35  
 Devriendt K, 45:217  
 Dewald GW, 45:179  
 Diaz de Bustamante A,  
 45:35  
 Di Cola M, 45:231  
 Dietrich CU, 45:161  
 Dittmar K, 48:75  
 Di Virgilio C, 50:277  
 Dmitrovsky E, 50:67  
 Dobbin J, 47:275  
 Domingo A, 50:227  
 dos Santos SA, 49:25  
 Drouin R, 48:265  
 Dry J, 46:271; 50:199  
 Duarte MHO, 49:25  
 Dubé ID, 49:113  
 Dufer J, 50:249  
 Dutrillaux A-M, 44:107  
 Dutrillaux B, 44:107,  
 44:131; 46:143,  
 49:37; 49:203  
  
 Ebert W, 49:185  
 Economopoulos T,  
 50:165  
  
 Egozcue J, 44:193;  
 46:251; 49:107;  
 49:133; 50:9  
 Einhorn S, 48:183  
 Eisenmenger E, 47:83  
 Elfving P, 46:191, 49:259  
 Eneroth M, 48:101  
 Erdel M, 49:185  
 Escribano L, 49:225  
 Ezpeleta I, 48:133  
  
 Faed MJW, 48:259  
 Fan S-X, 47:179  
 Farber M, 47:155  
 Farid NR, 44:119  
 Felix CA, 44:47  
 Feller A, 44:77; 50:15  
 Fenaux P, 46:173; 48:209  
 Ferre D, 45:197; 50:249  
 Ferro T, 49:225  
 Ferti-Passantonopoulou  
 A, 49:271; 50:165  
 Fisher C, 50:1  
 Fleming S, 45:81  
 Fletcher CDM, 48:31  
 Flodérus U-M, 44:27;  
 45:63; 46:65  
 Flüry-Hérard A, 49:37  
 Fonatsch C, 47:197  
 Ford J, 46:201  
 Ford JH, 44:99  
 Fordyce R, 47:163  
 Fossati G, 44:61  
 Fotiou S, 49:51  
 Foucar K, 45:179  
 Fox MF, 44:229; 46:129  
 Fraisse J, 48:281  
 Franssila KO, 48:109  
 Frisk B, 49:125  
 Fruchtman S, 46:185  
 Fryns J-P, 49:87  
 Fujieda H, 48:169  
 Fujita H, 49:117  
 Fujita N, 49:69  
 Fuster C, 49:107  
  
 Gahrton G, 45:143;  
 48:183  
 Gale RP, 46:107; 49:177  
 Gambaro F, 49:75  
 García de Miguel P,  
 45:35  
 Garré ML, 47:41  
 Garson OM, 46:201  
 Gatti RA, 46:1  
 Gaudray P, 49:143  
 Gedde-Dahl T, 47:69  
 Geleick D, 46:217  
 Genescà A, 46:251

- Genuardi M, 49:229  
Gerbault-Seureau M, 49:203  
Ghidoni A, 49:75  
Ghosh PK, 44:197; 44:203  
Ghosh R, 44:197; 44:203  
Ghosn C, 47:135  
Gibson SH, 47:227  
Gilliland G, 47:55  
Giudici A, 45:237; 45:269; 45:273  
Gödde E, 50:15  
Goetz P, 45:139  
Goolsby CL, 50:231  
Goosen LS, 47:101  
Gordon J, 46:89  
Gorman PA, 46:71; 48:193  
Goussot-J-F, 49:249  
Grammatico P, 48:237  
Granata P, 45:237; 45:273  
Grandchamp B, 48:209  
Granzow C, 48:23  
Grepp C, 44:1  
Grierson HL, 47:163  
Grison O, 49:249  
Grossman A, 48:75  
Grote W, 44:75; 50:15  
Groupe Français de Cytogénétique Hématologique, 44:169  
Guedea F, 49:107  
Guerrasio A, 46:243  
Guilhot F, 45:125  
Gullon A, 48:133  
Guntur M, 44:197; 44:203  
Gustavson K-H, 46:115  
Gustavsson I, 46:115  
Gusterson BA, 48:31  
  
Hackbarth DA, 47:61  
Hagemijer A, 47:1  
Hagmar L, 45:85  
Hall AP, 49:103  
Halme A, 48:1  
Han T, 50:171  
Hannan MA, 47:191  
Hansen MF, 49:15  
Hansteen I-L, 45:85  
Harless J, 50:45  
Harrington CI, 45:93  
Harris M, 45:245  
Harris RI, 45:261  
Hartley AL, 45:245  
Haupt R, 47:41  
Haus O, 48:281  
Havel G, 44:1  
Heath DV, 50:169  
  
Hecht BK, 46:9; 49:283  
Hecht F, 44:37; 45:277; 45:279; 46:9; 46:133; 47:271; 49:137; 49:283; 141  
Heerema NA, 46:41; 46:125  
Heim S, 44:27; 44:209; 45:63; 45:85; 46:65; 46:191; 48:101; 48:119; 48:217; 48:225; 49:95; 49:259; 49:273  
Helm G, 48:217  
Heyner S, 47:155  
Higuchi S, 47:277  
Hild F, 47:197  
Hill BT, 46:71  
Himmler A, 44:77  
Hobson EA, 47:101  
Hochsattel R, 45:161  
Högstedt B, 45:85  
Hollema H, 44:223  
Hoogsteden HC, 47:1  
Horn T, 50:139  
Horsman DE, 45:193; 45:249  
Hossfeld DK, 44:15  
Huber H, 50:189  
Humphries JE, 44:187  
Huret JL, 45:125  
Hutter K-J, 44:253  
  
Ichimaru M, 49:157; 50:149  
Ikeda S, 49:157  
Imanishi H, 49:219  
Inaba T, 49:69  
Inazawa J, 49:219  
Ingelaere H, 45:49  
Insel R, 46:271  
Ishihara T, 45:13  
Ishii K, 48:61  
Ishiwata I, 49:117  
Itoh K, 49:69  
Itoyama T, 49:157; 50:149  
Iwabuchi A, 45:73; 48:169  
Iwabuchi H, 45:73  
Iwahara Y, 48:61  
  
Jacob AK, 45:67  
Jacob G, 44:83  
Jacob J-L, 48:265  
Jani KH, 48:135  
Jankowska J, 46:29  
Jin Y, 44:27; 44:209; 49:95  
  
Johansson B, 48:119  
Johansson M, 48:225  
Jones MC, 47:243  
Jonveaux P, 49:265; 50:53  
Jotterand-Bellomo M, 44:271; 46:157  
Jouet JP, 48:209  
Jubashi T, 49:157  
Juhász F, 44:119  
Juliussen G, 45:143; 48:131; 48:183  
  
Kadam PR, 50:89; 50:109  
Kadota RP, 47:243  
Kakati S, 48:275  
Kalat M, 47:83  
Kallman KD, 50:45  
Kalousek DK, 45:193  
Kałużewski B, 46:29  
Kanda N, 48:229  
Kaneko Y, 47:171; 47:277; 50:273  
Kao YS, 45:265  
Karlic H, 50:189  
Kashima K, 49:219  
Kato H, 49:117  
Katz J, 45:207  
Kazuma M, 48:229  
Kees UR, 46:201  
Kelsey AM, 45:245  
Keltzel M, 47:89  
Kerckaert JP, 48:209  
Kerim S, 46:99; 46:243  
Keur Dvd, 48:179  
Khokhar MT, 47:249  
Kiechle-Schwarz M, 47:95  
Kirsch IR, 44:47  
Kleer E, 50:97  
Klein G, 46:93  
Knogler W, 50:189  
Knowles BB, 45:255  
Knudsen L, 45:85  
Knuutila S, 48:109  
Kobayashi H, 47:171  
Koeffler HP, 46:107  
Kohn G, 49:241  
Kohn S, 45:13  
Kovanen PE, 48:109  
Kowal-Vern A, 46:83; 50:31  
Kraemer PM, 48:89; 50:231  
Krespin HI, 45:131  
Kristoffersson U, 46:191; 48:119  
Krone W, 45:161  
Krous HF, 47:243  
Kubota K, 48:229



- Kujas M, 45:55  
 Kurvink K, 50:207;  
     50:265  
 Kuse R, 44:15  
 Kwan Y-L, 47:265  
  
 Lai JL, 46:173; 48:209  
 Lambert B, 45:85  
 Lam-Po-Tang PRL, 47:47  
 Laraña JG, 49:225  
 Larsen JK, 50:139  
 Laurence KM, 44:279  
 Laureys G, 45:49  
 Lawler SD, 47:249; 50:1  
 Le Baron F, 46:173  
 Le Coniat M, 44:69; 50:53  
 Lee EC, 45:101  
 Lee F-Y, 49:31  
 Lemieux N, 48:265  
 Lennert K, 50:15  
 Leonard C, 44:131  
 Leong SPL, 45:81;  
     47:113; 49:235  
 Leroy J, 45:49  
 Lester EP, 47:131  
 Li FP, 46:135  
 Liautaud-Roger F, 50:249  
 Libbus BL, 46:231  
 Licheri S, 47:273  
 Ligas C, 45:231  
 Limon J, 46:191; 49:259  
 Lin CC, 48:271  
 Lin C-T, 49:31  
 Lin D-T, 47:29  
 Lin K-H, 47:29  
 Lin M-T, 47:29  
 Linnainmaa K, 45:85  
 Lockhart LH, 50:169  
 Lockwood DH, 44:37  
 Löfvenberg E, 49:57  
 Logan JA, 45:41  
 London B, 49:113  
 Longmire J, 48:89  
 Longy M, 49:249  
 Lopes JM, 49:103  
 Lopez Pajares I, 45:35  
 Lo Re ML, 45:231; 48:237  
 Lothe RA, 47:69  
 Loucheux-Lefebvre MH,  
     48:209  
 Lukeis R, 46:201  
 Lukusa T, 49:87  
 Lundgren R, 46:191;  
     49:259  
  
 Maddrey WC, 45:255  
 Madhavi R, 44:197;  
     44:203  
 Malone M, 48:193  
  
 Mamon Z, 47:139  
 Mandahl N, 44:27;  
     44:209; 45:63; 46:65;  
     46:191; 48:101;  
     48:119; 48:217;  
     48:225; 49:95;  
     49:259; 49:273  
 Mandal AK, 44:279  
 Mangelschots K, 45:49  
 Mansberg R, 47:47  
 Månsson B, 48:225  
 Mariani T, 46:209  
 Mark J, 44:1; 44:153;  
     46:35; 47:141  
 Mark-Vendel E, 48:281  
 Martuza RL, 45:41  
 Marynen P, 45:217  
 Mascarello JT, 47:243  
 Maseki N, 47:171  
 Maserati E, 45:137  
 Massaad L, 44:131  
 Masuda M, 48:229  
 Matsuda I, 47:277; 50:273  
 Matter A, 46:217  
 Mauhin C, 49:249  
 Mayr B, 47:83  
 McBride OW, 44:47  
 McCombs JL, 50:169  
 McConnell TS, 45:179  
 McCormick C, 45:265  
 McKeithan TW, 49:219  
 Mecucci C, 48:49; 48:131;  
     49:171  
 Medchill M, 47:179  
 Meeker T, 48:183  
 Melnyk A, 46:83; 50:31  
 Merchant AA, 50:109  
 Mertens F, 48:119  
 Messier P-E, 48:265  
 Meulepas E, 49:87  
 Meyer K, 46:55  
 Meyne J, 48:271  
 Mezger J, 48:13  
 Michaux JL, 46:99  
 Milatovich A, 46:41  
 Miles BJ, 48:83  
 Milot J, 48:265  
 Minamihisamatsu M,  
     45:13  
 Minelli E, 45:237; 45:269;  
     45:273  
 Miozzo M, 44:61  
 Miró R, 46:251; 49:107;  
     50:9  
 Misawa S, 49:69; 49:219  
 Mitchell ELD, 47:107  
 Mitelman F, 44:27;  
     44:209; 45:63; 45:85;  
     46:65; 46:191;  
     48:101; 48:119;  
     48:225; 48:217;  
     49:95; 49:259; 49:273  
 Miura I, 48:203  
 Miyoshi I, 48:61  
 Mizoguchi H, 48:229  
 Mizui K, 50:75  
 Modesti A, 48:237  
 Mollevanger P, 48:179  
 Moltó E, 50:227  
 Monica K, 50:207  
 Montaldi A, 48:39  
 Moreau L, 46:89  
 Moreno S, 45:223  
 Moret M, 47:1  
 Morgan R, 44:47; 49:15  
 Morizot DC, 50:45  
 Morrell D, 46:21; 50:119  
 Morris Jones PH, 45:245  
 Mosna G, 49:75  
 Moyzis RK, 48:271  
 Mrózek K, 49:259  
 Mugneret F, 48:281  
 Muis N, 50:103  
 Muleris M, 44:107;  
     46:143  
 Müller H, 46:217  
 Munoz SJ, 45:255  
 Murakami S, 49:69  
 Murakami T, 47:277  
 Murty VVVS, 50:67  
  
 Naeim F, 49:177  
 Nairn RS, 50:45  
 Najfeld V, 46:185  
 Nakagawa H, 49:219  
 Nakagawa M, 49:69  
 Nakamura H, 49:157;  
     50:149  
 Nakanishi S, 49:69  
 Nash R, 50:1  
 Navarro JL, 49:225  
 Navarro S, 45:121  
 Nebraska Lymphoma  
     Study Group, 47:73  
 Nedoszytko B, 49:259  
 Neff JR, 47:61; 49:199  
 Neri G, 49:229  
 Nespoli L, 45:137  
 Neuman Y, 48:125  
 Ng JP, 45:261  
 Nicoletti B, 50:35  
 Niiya K, 48:61  
 Nikiforakis E, 49:271  
 Nilbert M, 44:27; 45:63;  
     48:217  
 Nilsson P-G, 48:119  
 Nishida K, 49:219




- Nishigaki H, 49:69;  
49:219  
Nishio A, 49:69  
Noguera R, 45:121  
Noll WW, 47:227  
Nomura Y, 48:229  
Noordhoek L, 50:103  
Nordenson I, 45:85; 49:57  
Nordic Study Group on  
the Health Risk of  
Chromosome  
Damage, 45:85  
Nordquist A, 46:35  
Noumoff JS, 47:155  
Nowell PC, 46:89  
  
Obara Y, 50:75  
Odriozola J, 49:225  
Ohtsuki Y, 48:61  
Ohyashiki JH, 45:73;  
48:169  
Ohyashiki K, 45:73;  
48:169  
Okada M, 48:229  
Oku N, 49:69  
Okuda T, 49:219  
Olah E, 44:119  
Olschwang S, 44:107  
Oosterhuis JW, 44:217;  
44:223; 46:75; 48:143  
Örndal C, 48:225; 49:95  
Orth G, 44:243  
Orts A, 45:1  
Oyarzabal FJ, 48:133  
  
Palau F, 45:1  
Palka G, 50:277  
Palmer CG, 46:41  
Panani AD, 49:271;  
50:165  
Panayotopoulos N, 49:51  
Pandis N, 49:51  
Parlier V, 44:271; 46:157  
Parr A, 44:181  
Pasino M, 47:41  
Pasquali F, 45:137  
Paterlini P, 45:231  
Patey M, 50:249  
Pati A, 45:261  
Patterson EJ, 47:55  
Paweletz N, 50:57  
Pedron S, 47:179  
Pejovic T, 46:65; 49:95  
Peltonmäki P, 48:1; 48:109  
Pereira MSO, 47:275  
Perez de Oteyza J, 49:225  
Perez-Sirvent ML, 45:1  
Perruca D, 49:143  
Peter M, 45:55  
Peter W, 49:185  
Peters GB, 44:99  
Petite J, 44:271  
Pettengill OS, 47:227  
Pettersson U, 46:115  
Phebus CK, 44:55  
Philippon J, 45:55  
Pierotti MA, 44:61  
Pinkerton PH, 49:113  
Piras A, 46:209  
Pirrucello S, 47:163  
Ploem JE, 48:179  
Porta F, 45:137  
Portensoso P, 45:269  
Porzucek L, 50:207  
Potter AM, 44:83  
Potter CW, 44:83  
Potter M, 46:93  
Powell I, 50:97  
Powles R, 47:249  
Prieto F, 45:1  
Prieur M, 44:131  
Pris J, 44:275  
Pritchard J, 48:193  
Privitera E, 49:75  
Prokocimer M, 49:241  
Pujol-Moix N, 50:227  
Purtilo DT, 47:163  
  
Qiu J-Y, 44:181  
Quagliano D, 45:231  
  
Rainaldi G, 46:209  
Ramesh KH, 44:37  
Ramot B, 47:139; 48:125;  
48:279  
Raptis S, 49:271; 50:165  
Ray M, 48:199  
Rechavi G, 48:125;  
48:279  
Rees RC, 44:83  
Reeves BR, 50:1  
Rege-Cambrin G, 46:99;  
46:243  
Regenass U, 46:217  
Reifinger M, 47:83  
Remvikos Y, 44:107  
Resau J, 48:203  
Resnitzky P, 47:139  
Reuterwall C, 45:85  
Rey JA, 45:223  
Richer C-L, 48:265  
Rivas C, 46:281  
Roberts CG, 48:53; 48:243  
Roberts SH, 44:279  
Robertson J, 48:259  
Rocchi M, 46:1  
Rödger S, 48:67  
Roloson GJ, 47:101  
  
Romain DR, 48:255  
Romano J, 50:171  
Romeo G, 46:1  
Rommel B, 49:165  
Rootman J, 45:249  
Rosenthal DS, 47:55  
Rosner E, 47:139; 48:125;  
48:279  
Rosso C, 46:243  
Rouleau G, 45:55  
Rouse BM, 50:169  
Rune C, 46:115  
Rydholm A, 48:101;  
48:217; 49:273  
  
Sacchi N, 46:1  
Sackey K, 47:191  
Sadamori N, 49:157;  
50:149  
Sage RE, 44:99  
Saglio G, 46:99  
Sakurai M, 47:171  
Sala E, 49:75  
Salmon R-J, 44:107;  
46:143  
Salomaa S, 45:85  
Salvador J, 50:9  
Salvidio E, 48:35  
Sandberg AA, 44:47;  
45:67; 45:81; 46:135;  
47:95; 47:113;  
47:179; 49:15;  
49:199; 49:235;  
50:171  
Sandros J, 44:153  
Sanford KK, 46:139  
Sanger WG, 47:73; 47:163  
Sansone R, 47:41  
Santos M, 46:281  
Saryusz-Wolska H, 46:29  
Sasagawa I, 49:157;  
50:149  
Sasi R, 48:271  
Sastre-Garau X, 44:243  
Sato T, 50:75  
Satyaswaroop PG, 47:155  
Saura R, 49:249  
Sawyer JR, 47:89; 47:101  
Scalise A, 46:185  
Scaravaglio P, 46:99  
Scarpa S, 48:237  
Schlegelberger B, 44:77;  
50:15  
Schleger W, 47:83  
Schloot W, 46:55; 49:165  
Schmidt C-G, 44:181  
Schmidt PM, 46:157  
Schneider-Maunoury S,  
44:243

- Schoenwald M, 45:125  
 Schouler L, 49:249  
 Schouten HC, 47:73  
 Schraffordt Koops H, 46:75  
 Schreck RR, 46:107  
 Schroeter D, 509:57  
 Schwartz C, 50:199  
 Schweiger P, 47:83  
 Schweizer D, 50:189  
 Secker-Walker LM, 49:1  
 Seizinger BR, 45:41  
 Senn JS, 49:113  
 Seruca R, 49:103  
 Sessarego M, 47:41; 48:35  
 Sfikas K, 49:51  
 Shah PM, 48:135  
 Sharma P, 47:47  
 Sheer D, 46:71; 48:193  
 Shen V, 50:153  
 Shen W-PV, 45:207  
 Shimazaki C, 49:69  
 Shiraishi Y, 50:175  
 Shlomai Z, 49:241  
 Sigut D, 47:191  
 Silberstein L, 46:89  
 Silva MLM, 47:275  
 Silva S, 46:93  
 Simi P, 45:237  
 Simi S, 46:209  
 Simon D, 45:255; 47:155  
 Simon M-P, 49:143  
 Sivakumaran M, 48:259  
 Skare J, 47:163  
 Skerfving S, 45:85  
 Skinnider L, 45:131  
 Skuse GR, 46:271; 50:199  
 Smith BP, 47:191  
 Smith M, 45:207  
 Smith MA, 48:31  
 Smith S, 48:31  
 Smith SD, 44:47  
 Soares LRM, 49:25  
 Solé F, 44:193; 49:133  
 Solero CL, 45:237  
 Söregi G, 50:189  
 Sorsa M, 45:85  
 Souza JM, 47:275  
 Sozzi G, 44:61  
 Sparkes RS, 46:107; 49:177  
 Speleman F, 45:49  
 Spiess E, 49:185  
 Spiga I, 49:75  
 Sreekantaiah C, 45:67; 45:81; 47:113; 47:179; 49:235  
 Sroka H, 45:249  
 Stallings R, 48:89  
 Stanley WS, 46:261  
 Stary J, 45:139  
 Steiner M, 50:231  
 Stejskalova E, 45:139  
 Stella M, 48:39  
 Stellan B, 49:125  
 Stenman G, 44:153; 46:35  
 Stenszky V, 44:119  
 Stern C, 46:55  
 Stracca-Pansa V, 48:39  
 Strauss PG, 47:219  
 Stul MS, 49:171  
 Stuppia L, 50:277  
 Subias A, 49:107  
 Suci S, 44:15  
 Sugiyama H, 46:93  
 Sun G, 46:107; 49:177  
 Sureda A, 49:225  
 Surti U, 47:95  
 Svendsen LB, 50:139  
 Svensson R, 50:45  
 Swift M, 46:21; 50:119  
 Swolin B, 48:67  
 Szepletowski P, 49:143  
 Tabak D, 47:275  
 Tada M, 48:229  
 Taguchi H, 48:61  
 Takai S, 46:139  
 Takeuchi T, 48:61  
 Tanaka S, 49:219  
 Taniwaki M, 49:69; 49:219  
 Tantravahi R, 47:55  
 Tanzer J, 45:125  
 Tarbell N, 50:125  
 Tarnow-Mordi WO, 48:259  
 Tarone RE, 46:139  
 Tarrida N, 44:193  
 Tattersall MHN, 48:53; 48:243  
 Tauchi T, 45:73  
 Tebbi CK, 48:275  
 Tedeschi B, 50:35  
 te Meerman GJ, 48:143  
 Terryberry S, 50:199  
 Tesmer J, 48:89  
 Testa JR, 48:203  
 Teyssier J-R, 45:197; 50:249  
 Tharapel SA, 47:131  
 Thomas G, 44:107; 45:55  
 Thorup J, 50:139  
 Tien H-F, 47:29; 49:31  
 Todd AS, 48:259  
 Tokunaga S, 49:157; 50:149  
 Toledano SR, 44:263  
 Tomiyasu T, 48:203  
 Tone LG, 49:25  
 Torhorst J, 46:217  
 Torrabadella M, 49:139  
 Toyama K, 45:73; 48:169  
 Trefz G, 49:185  
 Treleaven JG, 50:1  
 Triche TJ, 45:121  
 Tricot G, 46:125  
 Troy K, 46:185  
 Truglio F, 45:137  
 Tserkezoglou A, 49:51  
 Tsuchiya H, 47:277; 50:273  
 Tsuda S, 49:219  
 Tuerlings J, 50:103  
 Turc-Carel C, 48:281  
 Tyrkus M, 50:97  
 Ura Y, 49:69  
 Urata Y, 49:219  
 Valente AN, 47:275  
 Valiente A, 44:277  
 Vallespi T, 49:139  
 van den Berg E, 44:217  
 Vandenberghe EA, 48:49  
 Van Den Berghe H, 45:49; 45:217; 46:99; 46:243; 48:49; 49:87; 49:171  
 van der Kwast ThH, 47:1  
 Van Drunen E, 47:1  
 Van Dyke DL, 48:83  
 Vanni R, 47:273  
 Vatteroni L, 46:209  
 Vecchione D, 44:69; 50:53  
 Ventrone CH, 46:231  
 Verhoef GEG, 49:171  
 Vermeij B, 44:217  
 Vernole P, 50:35  
 Versnel MA, 47:1  
 Vespignani M, 48:39  
 Vial R, 45:265  
 Viegas-Péquignot E, 49:37  
 Vig BK, 509:57  
 Volk MS, 48:275  
 Vollrath M, 50:161  
 Vos A, 44:217; 44:223; 46:75; 48:143  
 Wada E, 48:229  
 Wahlin A, 49:57  
 Wake N, 49:117  
 Walter BN, 45:207  
 Wang C-H, 47:29

- Wang HC, 45:131  
Wang N, 46:271; 50:199  
Wang SY, 45:131  
Watmore AE, 44:83  
Wedell B, 44:1  
Weh HJ, 44:15  
Wei S, 46:1  
Weichselbaum RR, 50:125  
Weinberg M, 44:253  
Weinfeld A, 48:67  
Weinstein M, 48:75  
Weisenburger DD, 47:73  
Weiss L, 48:83  
Weiss R, 48:75  
Wendehorst E, 44:181  
Wenger SL, 44:55  
Wennerberg J, 44:209  
Werner E, 47:135; 49:277  
Wessels H, 48:179  
Westin J, 48:67  
Whang-Peng J, 45:101  
Wheby MS, 44:187  
Whelan R, 46:71  
White L, 47:265  
White VA, 45:249  
Wiener F, 46:93  
Wiley JE, 50:231  
Willén H, 44:27; 45:63; 46:65; 48:101; 48:217; 49:95; 49:273  
Williams G, 48:199  
Williams GJ, 47:249  
Willoughby MLN, 46:201  
Wilmanns W, 47:219  
Wiltshaw E, 50:1  
Wittekind C, 50:161  
Woessner S, 44:193; 49:133  
Wormsley S, 49:177  
Wurster-Hill DH, 47:227  
Wyandt H, 47:163  
Xiao H, 48:275; 50:171  
Yamada H, 49:117  
Yamada Y, 49:157  
Yamaguchi K, 47:277  
Yao E, 49:157  
Yaseen NY, 44:83  
Yip M-Y, 47:47; 47:265  
Yokoyama Y, 47:277  
Yongshan Y, 46:261  
Young R, 50:153  
Young RF, 45:207  
Zafaraullah KZ, 50:89  
Zafrani B, 49:203  
Zandecki M, 46:173  
Zech L, 49:125  
Zhang J, 45:217  
Zitzelsberger H, 47:219  
Zollino M, 49:229  
Zumel RM, 45:35





---

## Subject Index to Volumes 44-50

---

- Acrocentric chromosomes  
  interconnections, 50:207  
  NOR, 50:207  
  satellites, 50:207  
  variant NOR, 50:207
- Acute erythroleukemia (M6)  
  childhood, 49:25, 28 (Table)  
  chromosome analysis in the differential  
    diagnosis, 49:139; 50:89  
  chromosomes in, 48:67; 49:25; 50:89  
  MAKA pattern in, 50:89  
  secondary, 48:67
- Acute leukemia (AL)  
  biphenotypic, 47:265  
  complex chromosome changes and  
    congenital anomalies in a baby born  
    to a mother treated for AML, 50:169  
  ets-1 transposition, 50:199  
  hybrid with t(8;21), 49:177  
  in hydroxyurea-treated patients, 49:57  
  t(11;19) and biphenotypic, 50:199  
  +4 in biphenotypic, 47:265
- Acute lymphoblastic leukemia (ALL)  
  bcr in Ph+ ALL, 47:29  
  benzol and ALL, 49:133  
  biological importance of chromosome  
    changes, 49:1  
  BMT in, 45:137; 49:249  
  breakpoint characterization of t(14;14),  
    44:47  
  cell line of pre-B ALL, 46:201  
  chromosome changes in, 44:47, 69, 143,  
    45:137; 46:201; 47:29, 249; 48:229;  
    49:1, 50:31  
  clinical aspects, 49:1  
  cytogenetics and transplantation, 45:137  
  favorable prognosis in children with  
    hyperdiploidy, 50:273  
  hyperdiploidy and prognosis, 50:273  
  in XYY male, 49:215  
  late-appearing Ph, 48:35  
  Philadelphia-positive, 44:143; 47:29;  
    48:35; 49:1  
  ploidy in, 49:1  
  prognosis and chromosomes, 49:1  
  recurrence after BMT, 47:249  
  Rt locus in, 49:15  
  T-cell ALL cell line, 49:241  
  T-cell type, 44:47, 69; 48:229; 49:1, 69,  
    241; 50:31  
  t(1;8) in T-ALL, 50:31  
  t(4;11) in carcinogen exposed patient,  
    49:133  
  t(6;9)(p32;q34) and +13, 45:139  
  t(8;14)(q24;q11) in T-ALL, 49:69  
  t(14;14)(q11.2;q32) in T-ALL, 44:47  
  t(16;20) in cell line (T-ALL), 49:241  
  translocations in, 46:201, 47:29; 49:1,  
    69; 50:31  
  6, 7, 9, 12 and 14 in T-ALL, 44:69;  
    48:229
- Acute megakaryoblastic leukemia (M7)  
  cytogenetic findings, 48:119  
  translocations in, 48:119  
  21 and 22, 48:119
- Acute monocytic (monoblastic) leukemia  
  (M5)  
  chromosome changes in, 45:1; 47:249  
  chromosomes in, 46:99  
  i(11q) in M5a, 48:61  
  in children, 45:1  
  multiple clones, 47:171  
  9h in, 46:99  
  t(3;13) in, 49:277  
  unrelated clones, 47:171  
  11q23 in, 45:1
- Acute myeloblastic leukemia (M1)  
  chromosomes in, 47:139; 48:67  
  secondary, 48:67  
  t(16;21) in, 47:139
- Acute myeloblastic leukemia (M2)  
  chromosomes in, 46:185; 48:67; 50:103,  
    149  
  del(2)(p23) in, 46:185  
  secondary, 48:67  
  t(8;21) appearance, 50:149  
  8q22 involved, but not 21q22, 50:103
- Acute myelomonocytic leukemia (M4)  
  after 21 years of radon exposure, 48:125  
  chromosome changes, 45:1, 69, 261;  
    47:249; 48:125, 255, 50:103, 165  
  in children, 45:1  
  novel translocations, 44:99; 45:67,  
    50:165  
  radon induced?, 48:125  
  secondary, 50:165

- t(1;3) in secondary, 50:165  
 t(1;6)(p12;p23), 45:67  
 t(2;14) as sole change, 48:255  
 t(3;21)(q26-27;q22) and  
   t(15;21)(q21-22;q22) in ANLL, 44:99  
 t(11;13) and 7q-, 45:261  
 translocations in, 45:1, 69; 48:125, 255;  
   50:165  
 5q-, 5q- in M4 following MDS, 48:279  
 8q22 involved, but not 21q22, 50:103  
 11q23 in, 45:1  
 21q22 in ANLL, 44:99, 50:103  
**Acute nonlymphocytic leukemia (ANLL)**  
   APL (M3), 47:41; 50:109  
   BMT and recurrence, 47:249  
   chromosome changes, 44:99, 143, 169,  
     275; 45:1; 46:173; 47:139, 171, 249;  
     48:61, 67, 255; 50:103, 109  
   chromosomes in cryopreserved cells,  
     45:179  
   del(2)(p23) in M2, 46:185  
   in children, 45:1  
   in M4, 44:99; 45:1, 261; 48:255; 50:103  
   in M5, 45:1; 47:171; 48:61, 49:277  
   MDS and ANLL, 44:15; 46:173; 47:171  
   multiple clones, 47:171  
   neonatal in Down syndrome, 47:135  
   pentasomy 21q in AL in Down  
     syndrome, 47:135  
   Ph-positive, 44:143  
   secondary, 44:275; 46:173; 48:67; 49:57;  
     50:165  
   t(1;6)(p12;p23), 45:67  
   t(3;13) in, 49:277  
   t(8;21) in, 44:169; 50:149  
   t(16;21) in, 47:139  
   unrelated clones, 47:171  
   use of G-CSF, 47:277  
   +4 in undifferentiated AML, 45:265  
   11q23 in, 45:1  
   21q22 in, 44:99, 50:103  
**Acute promyelocytic leukemia (M3)**  
   chromosomes in, 45:193; 47:41; 50:109  
   disappearance of Ph in relapse, 47:41  
   Ph+ APL, 47:41; 50:109  
   promyelocytic blast phase of Ph+ CML  
     and t(15;17), 50:109  
   Robertsonian translocation, 45:193  
   Rt locus in, 49:15  
   secondary, 47:41  
   t(8;21) and t(9;22) in, 47:41  
   t(15;17) in blast phase of Ph+ CML,  
     50:109  
**Adenolymphoma; see Warthin's tumor**  
**Adenoma**  
   chromosome changes in, 44:153  
   parathyroid, 48:217  
   pleomorphic of salivary gland, 44:153;  
     46:55; 49:165  
   polyps of colon, 49:249; 50:139  
   renal, 49:125  
   thyroid, follicular, 44:119, 217  
**Angiofibroma**  
   chromosomes in, 45:161  
   in tuberous sclerosis, 45:161  
**Angioimmunoblastic lymphadenopathy  
 (AILD)**  
   chromosome changes in, 44:77; 50:15  
   four different clones in, 44:77  
   inv(14)(q11q32) in, 44:77  
   stepwise chromosome changes, 50:15  
**Askin tumor**  
   chromosome changes in, 47:89  
   effects of radiation, 47:89  
   t(11;22) in, 47:89  
**Astrocytoma**  
   anaplastic, 47:141  
   chromosomes, 47:101, 141  
   low-grade, 47:141  
   molecular studies in, 47:141  
   pontine, 47:101  
   1q trisomy in, 47:101  
**Ataxia-Telangiectasia (AT)**  
   cancer in, 46:9, 21, 133; 50:119  
   cancer in predisposition in  
     heterozygotes, 46:21; 50:119  
   carrier detection, 46:139  
   complications of AT, 46:9, 21  
   history of AT, 46:9  
   mapping of 11q23, 46:1, 133  
   molecular studies in, 46:1  
   neoplasms in AT, 46:9, 21, 133; 50:119  
   11q23 in, 46:1  
**Atherosclerosis**  
   chromosomes in plaque, 47:273  
   plaque, 47:273  
   +7 in plaque, 47:273  
**Basal cell carcinoma**  
   cytogenetic studies, 49:281  
**B-cell disorders**  
   ALL, 49:1  
   chromosomes in, 46:89  
   cold agglutinin disease, 46:89  
   lymphoma with t(14;19)(p32.3;q13.1),  
     49:219  
**B-cell growth factor (BCGF)**  
   effect on normal and neoplastic  
     lymphocytes, 48:109  
   effects, 48:109  
   in lymphoma, 48:109  
   proliferative effects, 48:109  
**BCR-ABL rearrangements**  
   chimeric transcripts, 48:209  
   in acute leukemia, 44:143; 47:29  
   in ALL, 44:143; 47:29  
   in ANLL, 44:143  
   in CML, 44:143, 277; 48:75, 209



- in masked Ph, 47:219
- in Ph+ ALL, 47:29
- in Ph+ CML in child, 44:277
- in Ph+ CML in treated HD, 49:171
- variant Ph, t(22;22), 48:209
- Benign tumors**
  - adenoma of thyroid, 44:119, 217; 50:249
  - chromosomes in, 44:1; 46:115; 47:95, 179; 50:249
  - dermoid of ovary, 49:95
  - leiomyoma, uterine, 44:1; 45:63, 47:95, 179
  - lipoma, 45:81; 47:113; 48:281, 49:235
  - meningiomas, 45:41, 237, 273; 47:141
  - neurinomas, 45:55
  - neurofibromatosis, 45:245
  - ovary, 44:223; 46:115; 48:243
  - salivary gland, 44:153; 46:35, 55
  - teratoma of ovary, 46:115
- Bladder tumors**
  - chromosome changes in, 46:129; 49:143; 50:9, 97
  - chromosome instability in cancer patients, 49:107
  - lymphocyte abnormalities, 49:107
  - marker chromosomes, 50:97
  - molecular genetics of carcinomas, 49:143
  - sex chromosome loss and prognosis, 50:97
  - X and -Y and disease course, 50:97
  - 5q- as only change in cancer, 46:129
  - +7 as a primary event, 50:1
- Blast crisis**
  - in Ph+ CML, 48:133; 50:109
  - lymphoid, 48:133
  - t(15;17) in promyelocytic, 50:109
  - 7 and dms, 48:133
- Bloom syndrome**
  - cytogenetic and immunologic aspects, 50:175
  - lymphoblastoid cell lines, 50:175
  - SCE in, 50:175
- Bone marrow**
  - cytogenetic studies in recurrence after grafts, 47:249
  - Hodgkin disease, 50:1
  - mastocytosis, 48:13
  - metastasis in neuroblastoma, 45:131
  - transplantation, 45:137; 46:83
- Bone marrow transplantation (BMT)**
  - allogenic, 47:55
  - autologous, 45:137
  - cytogenetic studies in recurrences, 47:249
  - cytogenetics in, 45:137; 46:83; 47:55, 249
  - in CML, 46:83; 47:55
  - leukemic recurrence in recipients of allografts, 47:249
  - MRD, 45:137
- Book reviews**
  - The Life and Times of Dr. Thomas Hodgkin, 49:283
- Brain tumors**
  - Askin tumor, 47:89
  - astrocytoma, 47:101; 47:141
  - classification, 47:141
  - ependymoma, 47:141
  - glioblastoma, 47:141
  - medulloblastoma, 47:141
  - meningiomas, 45:41; 47:141
  - neurinomas, 45:55
  - oligodendroglioma, 47:141
  - pontine astrocytoma, 47:101
  - Y in meningioma, 45:41
- Breast**
  - cancer, 46:217; 47:107; 49:203
  - cell lines, 46:271
  - cytogenetics of cancer, 46:217; 47:83, 107; 49:203
  - dic(5;11) in male cancer, 47:107
  - male cancer, 47:107
  - paradiploid cases, 49:203
  - SCE in leukocytes of girl with breast cancer, 44:203
  - tumor in dog, 47:83
  - two identical active X chromosomes, 46:271
- Burkitt lymphoma**
  - American (stage II), 48:275
  - chromosomes in, 48:275
  - 47,XY,+20,t(8;14) in, 48:275
- Cancer risk**
  - changes in lymphocytes and, 45:85; 49:107
  - chromosomal aberrations and, 45:85
  - chromosome changes and bladder cancer, 49:107
  - cytogenetic endpoints and, 45:85
  - in AT, 46:9
  - in heterozygotes of AT, 46:21
  - micronuclei and, 45:85
  - Nordic Study Group Report, 45:85
  - sister chromatid exchange (SCE) and, 45:85
- Canine tumor**
  - cytogenetics of mammary tumor, 47:83
  - mammary, 47:83
- Carcinoma in situ**
  - chromosomes, 46:75
  - of testis, 46:75
- Cell lines**
  - adenocarcinoma of lung, 49:185
  - adenomas, pleomorphic, 46:55
  - brain tumors, 47:141

- breast cancer, 46:271
- Chinese hamster cell lines, 46:209, 231
- effect of conditioned media, 46:107
- effects of retinoid-acid on melanoma cell line, 46:261
- esophageal cancer, 45:101
- germ cell tumors, 50:67
- Hirosaki sarcoma (rat), 50:75
- human-hamster hybrid, 48:89
- human sarcomas (radiation-induced), 50:125
- karyotype evolution in cell line, 50:231
- karyotypes of lung cancer lines, 49:185
- Krukenberg tumor, 46:71
- melanoma cell lines, 46:261; 48:237
- nasopharyngeal cancer, 49:31
- neuroblastoma, 45:131
- ovarian of Chinese hamster, 46:231
- pre-B ALL line, 46:201
- salivary adenoma developing a carcinoma, 44:253
- SK-UT-1B line (uterine leiomyosarcoma) is diploid, 48:139
- squamous cell carcinoma of lung, 49:185
- SV40-transformed fibroblasts, 50:231
- T-ALL with t(16;20), 49:241
- tumorigenic human cell line, 50:231
- vulvar intraepithelial lesion, 44:243
- Centromere
  - dicentric, 50:57
  - early replication of repetitive DNA, 50:57
  - inactive centromeres, 50:57
  - separation, 50:57
- Cervical cancer
  - chromosome changes in, 44:229
  - 1,3,4,5,11,14 and 17 in, 44:229
- Childhood
  - ANLL, 45:1
  - CMMoL and chromosome changes, 44:131
  - erythroleukemia, 49:25
  - leukemia treated and effects of chemotherapy in progeny, 50:169
- Chinese hamster
  - cell lines, 46:231, 217
  - chromosome changes in cell lines, 46:231
  - fragile sites in cell lines, 46:217
  - hamster-human hybrid cell line, 48:89
  - nutritional folate-deficiency, 46:231
  - ovary cell lines, 46:231
- Chondrosarcoma
  - chromosome changes in, 45:207
  - molecular analysis, 45:207
  - myxoid, 45:207
  - 10 and 22 in, 45:207
- Chromosome changes
  - in acute leukemia, Ph+, 44:143
  - in AILD, 44:77; 50:15
  - in ALL, 44:143; 46:107, 201; 47:29, 249; 49:1, 15, 133; 50:31
  - in AML, 44:169; 47:139; 50:103
  - in ANLL, 44:99, 143, 169; 45:1, 67, 193; 46:99, 107, 173; 47:139, 171, 249; 48:119; 49:115, 277
  - in APL, 47:41
  - in Askin tumor, 47:89
  - in bladder cancer, 49:143, 50:9
  - in brain tumors, 47:141
  - in breast cancer, 46:217; 47:107; 49:203
  - in cervical cancers, 44:229
  - in CIS of testis, 46:75
  - in CLL, 45:143; 50:171
  - in CML, 44:55, 143, 181; 45:13, 193; 46:83, 107; 47:55, 197; 48:75, 209; 49:15
  - in CMMoL, 44:15, 131; 46:99, 173
  - in cold agglutinin disease, 46:89
  - in colon polyps, 49:249
  - in dermatofibrosarcoma, 49:199, 273
  - in endometrial tumors, 46:1
  - in erythroleukemia, 50:89
  - in esophageal cancer, 45:269
  - in esophageal cancer (cell lines), 45:101
  - in Ewing sarcoma, 47:61, 89
  - in fibrosarcoma, 48:193; 49:199, 273
  - in germ cell tumors, 50:67
  - in Hodgkin disease, 50:1
  - in kidney tumors, 45:197
  - in large bowel cancer, 44:83; 44:107; 46:143
  - in leiomyomas, 44:1; 45:63; 47:89, 179; 49:51
  - in lipoma, 45:81; 47:113; 49:235
  - in liver tumor, 47:243
  - in lung tumors, 48:203; 49:37, 95, 185
  - in lymphoma, 44:279; 45:125, 231; 46:107; 47:73; 48:39; 49:219; 50:53
  - in MDS, 44:15, 27, 187; 45:73, 193; 46:107, 125, 157, 173, 243; 47:171, 275; 49:113
  - in melanoma, 44:61; 48:237
  - in meningioma, 45:41, 237, 273
  - in mesothelioma, 46:135; 47:1
  - in M2, 46:185
  - in M3, 45:193; 50:109
  - in M4, 44:99; 45:261; 50:103, 165
  - in M5, 46:99
  - in M7, 48:119
  - in neurinomas, 45:55
  - in osteosarcoma, 45:121; 50:125
  - in ovarian tumors, 44:223; 45:223; 46:65, 71, 115; 48:53, 243; 49:95, 50:67, 189

- in Philadelphia-positive acute leukemia, 44:143; 47:29
- in preleukemia, 49:15
- in progeny of mother treated for AML, 50:169
- in prostate cancer, 48:83
- in RA, 44:15; 46:157, 173
- in radiation exposure, 45:13
- in radiation-induced sarcomas, 50:125
- in RAEB, 44:15; 46:125, 157, 173
- in RAEB-t, 44:15; 46:157, 173
- in RARS, 44:15, 46:157
- in renal cell carcinoma, 45:197
- in salivary gland tumors, 44:153; 46:35, 55; 50:161
- in secondary leukemia, 44:275; 45:1; 46:173; 48:67, 175; 49:57, 171; 50:165
- in secondary MDS, 46:173
- in squamous cell carcinoma, 44:209; 47:131; 49:95
- in T-ALL, 44:47, 69; 48:229; 49:1, 69; 50:31
- in teratomas, 46:115
- in testis, 46:75; 48:1, 143; 50:67
- in thyroid tumors, 49:44, 199, 217; 47:227; 50:249
- in tuberous sclerosis, 45:161
- in uterine sarcomas, 44:27; 47:89; 48:217
- in uterine tumors, 46:1; 50:189
- in uveal melanoma, 45:249
- in Warthin's (adenolymphoma) tumor, 46:35
- in Wilms tumor, 45:35
- multiple clones in ANLL and MDS, 47:171
- unrelated clones in ANLL and MDS, 47:171
- Chromosome instability
  - human-hamster hybrids, 48:89
  - lymphocytes of bladder cancer patients, 49:107
  - SCE and, 48:89
  - Trans-acting factors, 48:89
- Chromosomes
  - 1 in cervical cancers, 44:229
  - in endometrial tumors, 46:41
  - in esophageal cancer, 45:101
  - in melanoma, 44:61
  - in myomas, 44:1
  - in ovarian cancer, 45:223
  - in thyroid tumors, 44:119
  - in uterine tumors, 46:41
  - 1p in large bowel cancer, 44:107
  - 1q in pontine astrocytoma, 47:101
  - 2 del(2)(p23) in M2, 46:185
  - in cold agglutinin disease, 46:89
  - in mesothelioma, 46:135
  - in myomas, 44:1
  - 3 in cervical cancer, 44:229
  - in esophageal cancer, 45:101
  - in lung tumors, 48:203
  - in ovarian cancer, 45:223
  - in renal cell carcinoma, 45:197
  - in uveal melanoma, 45:249
  - 3p in mesothelioma, 47:1
  - 4 del(4) in CML, 44:55
  - in cervical cancer, 44:229
  - in large bowel cancer, 44:107
  - +4 in ANLL, 45:265; 47:265
  - +4 in biphenotypic acute leukemia, 47:265
  - 4 in mesothelioma, 47:1
  - 5 del(5) in CML, 44:15
  - del(5) in MDS, 44:15; 46:157, 173
  - dic(5;11) in male breast cancer, 47:107
  - i(5p) in mesodermal tumor of ovary, 46:65
  - in cervical cancer, 44:229
  - in testis tumors, 48:1
  - +5 in mesothelioma, 47:1
  - 5q- in bladder cancer, 46:129
  - 5q in large bowel cancer, 44:107
  - 6 in CLL, 45:143
  - in CMMoL (-7), 44:131
  - in lymphoma, 47:73
  - in melanoma, 44:61
  - in myomas, 44:1
  - in ovarian cancer, 45:223
  - in renal cell carcinoma, 45:197
  - in T-ALL, 44:69; 48:229
  - 6p in MDS, 44:271
  - 7 in breast cancer, 46:217
  - in melanoma, 44:61
  - in myomas, 44:1; 47:179
  - in T-ALL, 44:69
  - in testis tumors, 48:1
  - +7 in bladder cancer, 50:9
  - +7 in mesothelioma, 47:1
  - +7, 7p and 7q in large bowel cancer, 44:83
  - 7/7q- in MDS, 44:15; 46:157; 48:67
  - 8 i(8q) in large bowel cancer, 44:83
  - in lung tumors, 48:203
  - in pleomorphic adenomas, 46:55
  - in uveal melanoma, 45:249
  - +8 in ANLL, 45:67
  - +8 in MDS, 44:15; 46:157
  - 8q and 8p in large bowel cancer, 44:107
  - 9 in esophageal cancer, 45:101
  - in renal cell carcinoma, 45:197
  - in T-ALL, 44:69
  - 9p in gliomas, 47:141
  - 9p in mesotheliomas, 47:1
  - 9p in ovarian cancer, 45:223



- 10 in endometrial cancer, 47:155  
in large bowel cancer, 44:107  
in myxoid chondrosarcoma, 45:207  
10q22 in myoma and leiomyosarcoma, 47:89
  - 11 in cervical cancer, 44:229  
in CLL, 45:143  
in esophageal cancer, 45:101  
in T-ALL, 44:69  
in thyroid tumors, 44:119  
+11 in large bowel cancer, 44:83, 107  
11q23 in ANLL, 45:1  
11q23 in AT, 46:1  
11q23 in MDS, 45:73
  - 12 i(12p) in CIS of testis, 46:75  
i(12p) in ovarian tumor, 45:49  
i(12q) in CLL, 50:171  
in CLL, 45:143  
in cold agglutinin disease, 46:89  
in mesothelioma, 46:135  
in myoma, 44:1; 47:179; 49:51  
in T-ALL, 44:69  
in testis tumors, 48:1; 50:67  
+12 in myomas, 45:63  
12p- in MDS, 44:15  
12q13-14 in lipoma, 47:113
  - 13 in CLL, 45:143  
in large bowel cancer, 44:83, 107  
in leukemia and preleukemia, 49:15  
+13 in MDS, 48:179  
13q14.11 in retinoblastoma, 48:265
  - 14 in cervical cancer, 44:229  
in CLL, 45:143  
in large bowel cancer, 44:107  
in myomas, 44:1; 47:179  
in T-ALL, 44:69  
inv(14) in AILD, 44:77  
14q11.2 in T-cell lymphoma, 48:39
  - 15 in large bowel cancer, 44:107
  - 16 in large bowel cancer, 44:107
  - 17 in breast cancer, 46:217  
in cervical cancer, 44:229  
in large bowel cancer, 44:83, 107; 46:143  
in lung tumors, 48:203  
in MDS, 44:15  
in renal cell carcinoma, 45:197  
17p in MDS and ANLL, 46:173  
17p in medulloblastoma, 47:141  
17p- in fibrosarcoma, 48:193
  - 18 in breast cancer, 46:217  
in large bowel cancer, 44:107; 46:143  
iso(18q) in lymphoma, 44:279
  - 19 +19 in MDS with thrombocytosis, 44:187
  - 20 in breast cancer, 46:217  
in large bowel cancer, 44:83  
+20 in hepatoblastoma, 47:243  
+20 in mesothelioma, 47:1  
20q- in MDS, 46:157
  - 21 in ANLL, 44:99  
in breast cancer, 46:217  
in large bowel cancer, 44:107  
in M7, 48:119  
pentasomy 1q in Down syndrome with ANLL, 47:135  
transient +21 in MPD, 48:259  
21q22 in M4, 44:99
  - 22 in meningioma, 45:273  
in myxoid chondrosarcoma, 45:207  
in M7, 48:119  
in neurinomas, 45:55, 237  
-22 in mesothelioma, 47:1
  - X in large bowel cancer, 44:107  
in myomas, 44:1
  - Y in esophageal cancer, 45:269  
-Y in MDS, 44:15; 46:157  
-Y in meningiomas, 45:41  
-Y in thorotrast exposure, 45:13
- Chronic lymphocytic leukemia (CLL)  
B-cell type, 45:143; 50:171  
chromosome changes, 45:143; 48:39; 183; 50:171  
clinical implications of cytogenetic changes, 45:143  
i(12q) in, 50:171  
molecular studies, 48:183  
no +12 or t(11;14) by molecular studies, 48:183  
normal karyotypes and molecular studies, 48:183  
T-cell type, 48:39  
6, 11, 13 and 14 in, 45:143  
+12 in, 45:143; 48:183
- Chronic myelocytic (myelogenous) leukemia (CML)  
bcr-abl changes, 44:143; 48:75; 209  
blast crisis with -7 and dms, 48:133  
BMT and chromosomes, 46:83; 47:55  
chromosome changes in, 44:55, 181; 45:13; 46:83; 47:55, 197, 219; 48:75, 209; 49:15  
chromosomes in cryopreserved cells, 45:179  
complex rearrangements with 7 breakpoints, 48:75  
i(17q) in (Ph-), 49:271  
in child with bcr rearrangement, 44:277  
in Hodgkin disease, 49:171  
in radiation exposure, 45:13  
juvenile type, 44:55  
Klinefelter syndrome and, 48:135  
masked Ph, 47:219  
multiple clones in, 47:55  
Ph chromosome, 44:181; 46:83; 47:197; 48:75, 209

- promyelocytic blast phase, 50:109
- Robertsonian translocation, 45:193
- t(15;17) in Ph+ CML in blast crisis, 50:109
- translocations in, 46:83; 47:55, 197; 48:75
- use of G-CSF, 47:277
- variant Ph, 44:181; 46:83; 47:197, 219; 48:209
- 4 and 5 in, 44:55
- Chronic myelomonocytic leukemia (CMMoL)
  - biclonal evolution, 44:131
  - chromosome changes in, 44:15, 131; 46:99, 157, 173
  - expression of FRA16B, 49:229
  - heterochromatin involvement, 46:99
  - in a child, 44:131
  - multiple clones, 47:171
  - prognostic and survival aspects, 44:15; 46:157, 173; 50:227
  - secondary (therapy-related), 46:173; 50:227
  - t(3;21) in, 50:227
  - unrelated clones, 47:171
- Cold agglutinin disease
  - B-cell and, 46:89
  - chromosomes, 46:89
  - +3 and +12 in, 46:89
- Colorectal tumors; see Large bowel
- Culture
  - brain tumors, 47:141
  - establishment of cell line (ALL), 46:201
  - of MDS cells, 46:157
  - of prostatic cancer cells, 46:191
- Culture media
  - conditioned, 46:107
  - factors of conditioned medium, 46:107
  - masking of chromosome changes in leukemia and, 46:107
- Cytogenetics
  - in ALL, 44:143; 46:107, 201; 47:29, 249; 49:1, 15, 133; 50:31
  - in AML, 44:169; 47:139; 50:103
  - in ANLL, 44:99, 143, 169; 45:1, 67, 193; 46:99, 107; 47:139, 171, 249; 48:119; 49:115, 277, 50:103, 161
  - in APL, 47:41; 50:109
  - in Askin tumor, 47:89
  - in bladder cancer, 49:143; 50:9
  - in brain tumors, 47:141
  - in breast cancer, 46:217; 47:107; 49:203
  - in cervical cancers, 44:229
  - in CIS of testis, 46:75
  - in cold agglutinin disease, 46:89
  - in colon polyps, 49:249
  - in dermatofibrosarcoma, 49:194, 273
  - in endometrial tumors, 46:41; 50:189
  - in erythroleukemia, 50:89
  - in esophageal cancer, 45:269
  - in esophageal cancer (cell lines), 45:101
  - in Ewing sarcoma, 47:61, 89
  - in fibrosarcoma, 48:193; 49:199, 273
  - in germ cell tumors, 50:67
  - in Hodgkin disease, 50:1
  - in kidney tumors, 45:197
  - in lipoma, 45:81; 47:113, 49:235
  - in liver tumor, 47:243
  - in lung tumors, 48:203; 49:37, 95, 185
  - in lymphoma, 44:279; 45:125, 231; 46:107; 47:73; 48:39; 49:219; 50:53
  - in meningiomas, 45:41, 237, 273
  - in mesothelioma, 46:135; 47:1
  - in M2, 46:185
  - in M3, 45:193
  - in M4, 44:99; 45:261
  - in M5, 46:99
  - in M7, 48:119
  - in neurinomas, 45:55
  - in osteosarcoma, 45:121; 50:125
  - in ovarian tumors, 44:223; 45:223; 46:65, 71, 115; 48:53, 243; 49:95, 50:67, 189
  - in Philadelphia-positive acute leukemia, 44:143; 47:29
  - in progeny of mother treated for AML, 50:169
  - in prostate cancer, 48:83
  - in radiation exposure, 45:13
  - in radiation-induced sarcomas, 50:125
  - in renal cell carcinoma, 45:197
  - in salivary gland tumors, 44:153; 46:35, 55; 50:161
  - in secondary leukemia, 44:275; 45:1; 46:173; 48:67, 125; 49:57, 171; 50:165
  - in secondary MDS, 46:173
  - in squamous cell carcinoma, 44:209; 47:131
  - in teratoma, 46:115
  - in testis, 46:75; 48:1, 143; 50:67
  - in uterine tumors, 46:41; 59:189
  - in uveal melanoma, 45:249
  - in Warthin's tumor (adenolymphoma), 46:35
  - in Wilms tumor, 45:35
  - multiple clones in ANLL and MDS, 47:171
  - of acute leukemia, Ph+, 44:143
  - of AILD, 44:77; 50:115
  - of CLL, 45:143; 50:171
  - of CML, 44:55, 143, 181; 45:13, 193; 46:83; 107; 47:55, 197; 48:75, 209; 49:15
  - of CMMoL, 44:15, 131; 46:99, 157, 173
  - of large bowel cancers, 44:83, 107; 46:143
  - of MDS, 44:15, 187, 271; 45:73, 193;

46:107, 125, 157, 173, 243; 47:171, 275; 49:113  
 of melanoma, 44:61; 48:237  
 of preleukemia, 49:15  
 of refractory anemias, 44:15; 46:157, 173  
 of T-ALL, 44:47, 69; 48:229; 49:1, 69; 50:31  
 of thyroid tumors, 44:119, 217; 47:227  
 of tuberous sclerosis, 45:161  
 of uterine myomas, 44:1; 45:63; 47:89, 179; 49:51  
 of uterine sarcomas, 44:27; 47:89; 48:217  
 unrelated clones in ANLL and MDS, 47:171

#### Deletions

del(2)(p23) in M2, 46:185  
 in AILD, 50:15  
 in ANLL, 45:1, 46:173  
 in breast cancer, 46:217; 49:203  
 in cervical cancers (1p-,3p-), 44:229  
 in CLL, 45:143  
 in CMMoL, 44:131  
 in Hodgkin disease, 50:1  
 in hydroxyurea-treated cases of MPD, 49:57  
 in large bowel cancers, 44:83, 107; 46:143  
 in leiomyosarcoma, 47:89  
 in lung cancer, 49:37  
 in lung tumors, 48:203; 49:37  
 in lymphoma, 45:125; 49:265; 50:1, 53  
 in MDS, 44:15; 47:275  
 in melanoma, 44:61  
 in mesothelioma, 47:1  
 in myomas, 44:1; 47:89  
 in ovarian tumors, 48:53, 243  
 in salivary gland tumors, 44:153; 46:55; 50:161  
 in squamous cell carcinoma, 44:209  
 3p- in renal adenoma, 49:125  
 4p- in renal cell carcinoma, 49:125  
 4q- in CML, 44:55  
 5q- in CML, 44:55  
 5q- in MDS, 44:15; 46:157, 173; 47:171, 275; 48:67  
 6q in lymphoma, 47:73  
 6q- in T-ALL, 44:69; 48:229  
 7q- in MDS, 44:15; 46:157, 173  
 7q- in M4, 45:261  
 9p- in gliomas, 47:141  
 9p- in T-ALL, 44:69  
 11q- in thyroid tumor, 44:119; 47:227  
 12p- in MDS, 44:15; 47:275  
 12p- in T-ALL, 44:69  
 13q in leukemia and preleukemia, 49:15  
 13q14.11 in retinoblastoma, 48:265  
 17p- in fibrosarcoma, 48:193

20q- in MDS, 46:157  
 Xq25 in XLP, 47:163  
 Derivative chromosomes  
 in breast cancer, 49:203  
 in CIS of testis, 46:75  
 in CMMoL, 44:131  
 in Hodgkin disease, 50:1  
 in Krukenberg tumor, 46:71  
 in large bowel cancer, 44:83, 107; 46:143  
 in lymphoma, 45:125; 47:73; 50:1  
 in MDS, 45:73; 46:157, 173  
 in mesothelioma, 47:1  
 in salivary gland tumors, 46:55  
 in thyroid cancer, 47:227  
 Dermatofibrosarcoma protuberans  
 cytogenetics of, 49:199, 273  
 in old burn scar, 49:199  
 ring chromosome in, 49:273  
 +8 and +8,+r in, 49:199  
 Dermoid cysts; see Teratoma  
 Desmoid cyst  
 chromosomes in, 44:223  
 DNA levels in, 44:223  
 ovarian, 44:223  
 Dicentric chromosome  
 dic(5;11) in male breast cancer, 47:107  
 in medullary thyroid cancer, 47:227  
 DNA levels  
 DNA content and karyotypes in thyroid tumors, 50:249  
 in ovarian tumors, 44:223  
 in testicular tumors, 48:143  
 with flow cytometry, 44:223  
 DNA rearrangements  
 in acute leukemia, 50:199  
 in AT at 11q23, 46:1  
 in bladder tumors, 49:143  
 in brain tumors, 47:141  
 in CLL, 48:183  
 in CML, 44:143, 277; 47:219; 48:75; 49:15  
 in large bowel cancer, 44:107  
 in leukemia and preleukemia, 49:15  
 in lymphoma, 49:219  
 in MDS, 45:73; 46:243  
 in neurinomas, 45:55  
 in ovarian teratomas, 46:115  
 in Ph+ acute leukemia, 44:143; 47:29  
 in Ph+ ALL, 47:29  
 in salivary gland tumors, 44:153; 48:209  
 in T-ALL, 44:47; 48:229; 49:69  
 in TCRA, 44:47; 46:281  
 in testis tumors, 48:1  
 of Y in meningiomas, 45:41  
 masked Ph, 47:219  
 Double minute chromosomes (DMS)  
 in blast crisis (lymphoid) of Ph+ CML, 48:133



- in brain tumors, 47:141
- in erythroleukemia, 50:89
- in hepatoblastoma, 47:243
- in Krukenberg tumor cell line, 46:71
- in leukocytes of girl with breast cancer, 44:203
- in murine transformed cells, 49:75
- no telomere sequences in, 48:271
- Down syndrome
  - ANLL in, 47:135
  - Ewing sarcoma with t(11;22) in, 47:61
  - neonatal acute leukemia, 47:135
  - pentasomy of #21, 47:135
  - skeletal Ewing sarcoma in, 47:61
- Electron Microscopy
  - and hereditary retinoblastoma, 48:265
  - detection of deletion at 13q14.11, 48:265
- Endometrial tumors; see also Uterus
  - cell hybridization, 49:117
  - cell lines, 49:117
  - chromosome 10, 47:155
  - chromosomes in, 46:41; 47:155; 50:189
  - malignancies, 46:41; 50:189
  - malignant mixed müllerian tumor, 46:41
  - resistance to 6-thioguanine and G-418, 49:117
  - 1q in, 46:41
- Ependymoma
  - cytogenetics of, 47:141
- Epidermal growth factor receptor (EGFR)
  - expression, 46:261
  - in melanoma cell line, 46:261
  - retinoic acid effects, 46:261
- Epiglottis
  - cytogenetics of, 49:95
  - numerical chromosome changes, 49:95
  - squamous cell carcinoma, 49:95
- Erythroleukemia; see Acute erythroleukemia
- Esophageal cancer
  - cell lines, 45:101
  - cytogenetic studies, 45:101; 45:269
  - epidermoid carcinoma, 45:269
  - HSR in cell lines, 45:101
  - 1, 3, 9 and 11 in cell lines, 45:101
  - +Y and fra(X)(q28) in cancer, 45:269
- Ewing sarcoma
  - chromosomes in, 47:61
  - in Down syndrome, 47:61
  - primary skeletal, 47:61
  - t(11;22) in, 47:61
- FAB classification
  - chromosomes in M1, 47:139
  - chromosomes in M2, 44:169; 46:185
  - chromosomes in M3, 47:41
  - chromosomes in M4, 44:99; 45:1, 67
  - chromosomes in M5, 45:13; 46:99
  - chromosomes in M7, 48:119
  - in MDS and chromosomes, 44:15; 46:157, 173
  - MDS vs M6, 49:139
- Familial tumors and diseases
  - ataxia-telangiectasia, 50:119
  - neurofibromatosis, 45:245
  - sarcomas in neurofibromatosis, 45:245
  - T-cell leukemia, 49:157
  - X-linked lymphoproliferative disease (XLP), 47:163
- Fibroblasts
  - cell line, SV40-transformed and karyotype evolution, 50:231
  - chromosomes in, 45:161
  - from café-au-lait spot of NF, 47:191
  - from normal skin of NF, 47:191
  - in tuberous sclerosis, 45:161
  - radiosensitivity in NF-6, 47:191
  - tetraploidy (in vitro) in colorectal cancer, 50:139
- Fibrosarcoma
  - chromosome changes, 48:193
  - congenital, 48:193
  - 17p-, 48:193
- Fish(es)
  - erbB-like DNA, 50:45
  - genus *Xiphophorus* and linkage group VI, 50:45
- Fragile sites
  - aphidicolin and, 50:35
  - Chinese hamster cell lines, 46:209
  - chromosomal, 44:37
  - expression of FRA16B, 49:229
  - folate-sensitive, 46:209
  - fragile(X)(q28) in esophageal cancer, 45:269
  - FRAXD at Xq27.2, 49:137
  - FRA16B in lymphocytes and marrow, 49:229
  - guide to, 44:37
  - in melanoma cells, 44:61
  - in neuroblastoma, 50:35
  - in parents of neuroblastoma cases, 50:35
  - SCE at Xq27.3 fragile site, 49:87
- Gains
  - in brain tumors, 47:141
  - in large bowel cancer, 46:143
  - in mesothelioma, 47:1
  - in testis tumors, 48:143
  - in thyroid cancer, 47:227
  - of chromosomes in large bowel cancer, 44:107
- Germ cell tumors; see also Ovary and Testis
  - in pineal region without i(12p), 50:153
- Glioblastoma
  - cytogenetics of, 47:141

- giant cell, 47:141
- molecular studies, 47:141
- multiform, 47:141
- Gliosarcoma
  - chromosomes in, 47:141
- Growth factors
  - effect on MDS cells, 48:169
  - hematopoietic growth factors, 48:169
  - recombinant, 48:169
- Head and Neck
  - chromosomes in SCC, 47:131; 49:95
  - epiglottis cancer, 49:95
  - squamous cell carcinoma (SCC), 47:131
- Hepatoblastoma; see Liver
- Hepatocellular carcinoma; see Liver
- Heterochromatin
  - involvement in monocytic leukemia, 46:99
  - 1h, 4h and 9h in monocytic leukemia, 46:99
- Hodgkin disease (HD)
  - chromosome changes, 50:1
  - Ph+ CML in treated HD, 49:171
  - serial studies, 50:1
- Homogeneously staining regions (HSR)
  - in breast cancer, 49:203
  - in esophageal cancer cell lines, 45:101
  - in murine-transformed cells, 49:75
- HTLV-I carriers
  - chromosomes in lymphocytes, 49:157
  - family study, 49:157
- Human Gene Mapping 10 (1989)
  - book review, 49:141
- Hybrid leukemia
  - t(8;21) in, 49:177
- Inversion
  - in breast cancer, 46:217
  - in large bowel cancer, 46:143
  - in mesothelioma, 47:1
  - in salivary gland tumors, 46:55
  - inv(14) in angioimmunoblastic lymphadenopathy, 44:77
- Isochromosomes
  - double i(18q) in lymphoma, 44:279
  - i(5p) in mesodermal tumor of ovary, 46:65
  - i(6p) and i(6q) in melanoma, 44:61
  - i(6p) in lymphoma, 47:73
  - i(7q) in melanoma, 44:61
  - i(8q) in lung tumors, 48:203
  - i(8q) in uveal melanoma, 45:249
  - i(11q) in M5a, 48:61
  - i(12p) in CIS of testis, 46:75
  - i(12p) in malignant ovarian tumor (yolk sac), 45:49
  - i(12p) in testis tumors, 48:1, 143
  - i(12q) in CLL, 50:171
  - i(17q) in CML (Ph-), 49:271
  - i(18q) in lymphoma, 44:279
  - in breast cancer, 49:203
  - in cervical cancers, 44:229
  - in large bowel cancer, 44:83, 107; 46:143
  - in MDS, 46:157
  - in mesothelioma, 47:1
  - pseudodicentric isochromosome 22 in meningioma, 45:273
  - 14q in MDS, 49:113
- Karyotypes
  - in APL, 47:41; 50:109
  - in Askin tumor, 47:89
  - in brain tumors, 47:141
  - in CMMoL, 44:15, 131; 46:99, 157, 173
  - in Ewing sarcoma, 47:61, 89
  - in hydroxyurea-treated cases, 49:57
  - in liver tumor, 47:243
  - in MDS, 44:15, 187, 271; 45:73, 193; 46:107, 125, 157; 173, 243; 47:171, 275; 49:113
  - in melanoma, 44:61; 48:237
  - in progeny of mother treated for AML, 50:169
  - in prostate cancer, 48:83
  - in testis, 46:75, 48:1, 143, 50:67
  - in uterine myomas, 44:1; 45:63; 47:89, 179, 49:51
  - multiple clones in MDS and ANLL, 47:171
  - of acute leukemia, Ph+, 44:143
  - of AILD, 44:77; 50:15
  - of ALL, 44:143; 46:107, 201; 47:29, 249; 49:1, 15, 133; 50:31
  - of AML, 44:169; 47:139; 50:103
  - of ANLL, 44:99, 143, 169; 45:1, 67, 193; 46:99, 107; 47:139, 171, 249; 48:119; 49:115, 277; 50:103
  - of bladder cancers, 49:143; 50:9
  - of breast cancer, 46:217; 47:107; 49:203
  - of cervical cancers, 44:229
  - of CIS of testis, 46:75
  - of CLL, 45:143; 50:171
  - of CML, 44:55, 143, 181; 45:13, 193; 46:83, 107; 47:55, 197; 48:75, 209; 49:15
  - of cold agglutinin disease, 46:89
  - of colon polyps, 49:249
  - of dermatofibrosarcoma, 49:199, 273
  - of endometrial tumors, 46:41; 50:189
  - of erythroleukemia, 50:89
  - of esophageal cancer, 45:101, 269
  - of fibrosarcoma, 48:193; 49:199, 273
  - of germ cell tumors, 50:67
  - of Hodgkin disease, 50:1

- of kidney tumors, 45:197
- of large bowel cancer, 44:83, 107; 46:143
- of lipoma, 45:81; 47:113; 49:235
- of lung tumors, 48:203; 49:37, 95, 185
- of lymphoma, 44:279; 45:125, 231; 46:107; 47:73; 48:39; 49:219; 50:53
- of meningiomas, 45:41, 237, 273
- of mesothelioma, 46:135; 47:1
- of M2, 46:185
- of M3, 45:193
- of M4, 44:99; 45:261; 50:103
- of M5, 46:99
- of M7, 48:119
- of neurinomas, 45:55
- of osteosarcoma, 45:121; 50:125
- of ovarian tumors, 44:223; 45:223; 46:65, 71, 115; 48:53, 243; 49:95; 50:67, 189
- of Philadelphia-positive acute leukemia, 44:143; 47:29
- of radiation exposure, 45:13
- of radiation-induced sarcomas, 50:125
- of refractory anemias, 44:15; 46:157, 173
- of renal cell carcinoma, 45:197
- of salivary gland tumors, 44:153; 46:35, 55; 50:161
- of secondary leukemia, 44:275; 45:1; 46:173; 48:67, 125; 49:57, 171
- of secondary MDS, 46:173
- of squamous cell carcinoma, 44:209; 47:131
- of T-ALL, 44:47, 69; 45:67, 137; 48:229; 49:1, 69; 50:31
- of teratoma, 46:115
- of thyroid tumors, 44:119, 217; 47:227; 50:249
- of tuberous sclerosis, 45:161
- of uterine sarcomas, 44:27; 47:89; 48:217
- of uterine tumors, 46:41; 50:189
- of uveal melanoma, 45:249
- of Warthin's tumor (adenolymphoma), 46:35
- of Wilms tumor, 45:35
- unrelated clones in MDS and ANLL, 47:171
- Kidney tumors
  - and von Hippel-Lindau disease, 49:125
  - bilateral renal carcinomas, 49:125
  - chromosome changes, 45:197; 49:125
  - del(3) in adenoma, 49:125
  - del(4) in renal cell carcinoma, 49:125
  - in Wiedemann-Beckwith syndrome, 45:35
  - lymphangioma with 45,X,-X,i dic(7q), 46:29
  - renal cell carcinoma, cytogenetics, 45:197; 49:125
  - significance of +7 and loss of sex chromosomes, 49:259
  - Wilms tumor, 45:35
    - 3, 7, 9 and 17 in renal cell cancer, 45:197
    - +7 and sex chromosome loss, 49:259
- Klinefelter syndrome
  - CML (Ph+), 48:135
- Krukenberg tumor
  - chromosomes in, 46:71
  - of ovary, 46:71
- Large bowel
  - chromosomes and lymphocytes of polyposis cases, 47:69
  - chromosomes in colorectal tumors, 44:83; 44:107; 46:143; 49:249; 50:139
  - cytogenetics of polyps, 49:249
  - i(7p) and der(17) as only changes in two cancers, respectively, 44:83, 107
  - i(8q) in rectosigmoid tumor, 44:83, 107
  - molecular and cytogenetic data, 46:143
  - polyploidization in cancer, 44:107; 50:139
  - polyposis cases in Norway, 47:69
  - tetraploidy (in vitro) in sporadic cancer, 50:139
  - 7, 17, 8, 11, 13 and 20 in large bowel cancer, 44:83, 107; 46:143
  - +7 and +13 in polyps, 49:249
  - +11 in colorectal cancer, 44:83, 107
  - 20p- and dup(20q) in colorectal cancers, 44:83, 107
- Larynx
  - chromosome changes in cancer, 44:209
  - squamous cell carcinoma, 44:209
- Leiomyomas
  - chromosomes in, 44:1; 45:63; 47:89, 179; 49:51
  - uterine, 44:1; 45:63; 47:89, 179; 49:51
  - 7, 12 and 14, 47:179
  - 10q22 in, 47:89
  - 12q14 in, 49:51
- Leiomyosarcoma
  - chromosomes in, 44:27; 47:89; 48:217
  - subcutaneous, 48:217
  - uterine, 44:27; 47:89; 48:217
  - 10q22 in, 47:89
  - 12q13 and 14q24 in, 48:217
- Leukemia cells
  - chromosomes in preserved cells, 45:179
  - cryopreserved, 45:179
- Lipoma
  - chromosome changes, 45:81; 47:113; 48:281
  - complex chromosome anomalies, 47:113
  - t(1;6) in, 48:281
  - t(2;6)(q36;p21.3) in, 45:81
  - t(X;12) in, 49:235
  - 6p in, 48:281
  - 12q13-14 in, 47:113



- Liposarcoma  
t(12;16) in, 48:101  
12q13.3 and 16p11.2, 48:101
- Liver  
chromosome changes in cancer, 45:255;  
47:243  
hepatoblastoma, 47:243  
hepatocellular carcinoma, 45:255  
+10 and dms in hepatoblastoma, 47:243
- Loss of heterozygosity (LOH)  
in bladder cancers, 49:143  
in breast cancer, 49:215 (Table)  
in large bowel cancer, 46:143  
in leukemia and preleukemia, 49:15  
in MDS, 46:243  
in neurinomas, 45:55  
in testis tumor, 48:1
- Lung cancer  
adenocarcinoma, 49:95, 185  
cell lines, 49:185  
chromosome changes, 48:203; 49:37, 95,  
185  
i(8q) in, 48:203  
numerical changes, 49:95  
squamous cell carcinomas, 49:37, 185  
3p and 17p, 48:203  
3p- in, 49:37
- Lymphangioma  
of kidney, 46:29  
45,X,-X,i dic(7q) in, 46:29
- Lymphocytes  
acrocentric, interconnections, 50:207  
NOR variants, 50:207
- Lymphoma  
chromosome changes in, 45:125; 47:73;  
48:39, 109, 199; 49:219; 50:53  
chromosome 6 in NHL, 47:73  
cold agglutinin disease and, 46:89  
del(7)(p13p14), 50:53  
deletions in, 49:265; 50:53  
double i(18q) in, 44:279  
effects of BCGF, 48:109  
follicular; small cleaved cell, 48:199  
histologic subtypes, 47:73  
Hodgkin disease, 50:1  
i(18q) in, 44:279  
in AT, 46:9  
molecular studies, 49:219  
Sézary syndrome, 44:193; 45:231; 46:281  
t(8;9)(q12;p21), 45:125  
t(14;18) and t(8;11) in follicular, 48:199  
t(14;19) in B-cell, 49:219  
T-cell, peripheral, 48:39
- Makino, Sajiro  
obituary, 44:139
- Malignant fibrous histiocytoma (MFH)  
chromosomes in, 50:125, 189  
secondary (radiation-induced), 50:25
- Mammary tumors; see Breast
- Mastocytosis  
chromosome changes, 48:13  
in bone marrow, 48:13  
malignant, 48:13
- Medulloblastoma  
cytogenetics of, 47:141
- Melanoma  
cell lines, 46:261; 48:237  
chromosome changes in, 44:61; 48:237  
EGFR expression in cell line, 46:261  
fragile sites in, 44:61  
malignant, 44:61; 48:237  
significance of chromosome changes, 48:237  
uveal, 45:249  
1, 6 and 7 in, 44:61  
-3 and i(8q) in uveal, 45:249
- Meningioma  
chromosomes in, 45:41, 237; 47:141  
corrected figure psu iso(22) in 45:273;  
48:284  
histopathologic and chromosomal  
correlations, 45:237  
molecular studies (-Y) in, 45:41  
pseudodicentric isochromosome 22,  
45:273  
-Y in, 45:41
- Mesodermal tumor  
chromosomes in, 44:27  
malignant of ovary, 46:65  
mixed, 44:27, 46:65
- Mesothelioma  
asbestos exposure, 47:1  
chromosomes in, 46:135; 47:1  
peritoneal, 46:135  
pleural and pericardial, 47:1  
3 and 12p in, 46:135  
-4, -22, 9p- and 3p-, 47:1  
+5, +7 and +20, 47:1
- MIC IV (Conference on the Morphologic,  
Immunologic, and Cytogenetic  
Classification of Chronic (Mature) B  
and T Lymphoid Leukemias  
report, 48:131
- Micronuclei  
cancer risk and, 48:85  
in lymphocytes, 45:85
- Molecular studies  
EGFR in melanoma cell line, 46:261  
in acute leukemia with t(11;19), 50:199  
in ALL, 49:15; 46:69  
in AML, 49:15  
in AT, 46:1  
in bladder cancer, 49:143  
in brain tumors, 47:141  
in breast cancer line, 46:271  
in chondrosarcoma (myxoid), 45:207  
in CLL, 48:183

- in CML, 44:143, 277; 47:219; 48:75, 209; 49:15
- in hybrid leukemia with t(8;21), 49:177
- in large bowel cancer, 44:107
- in lymphoma, 49:219
- in MDS, 45:73; 46:243
- in melanoma cell line, 46:261
- in meningiomas (-Y), 45:41
- in Ph+ acute leukemia, 44:143; 47:29
- in Ph+ ALL, 47:29
- in preleukemia, 49:15
- in salivary gland tumors, 44:153
- in T-ALL, 44:47; 48:229; 49:69
- in teratoma of the ovary, 46:115
- in testis tumors, 48:1
- masked Ph, 47:219
- of *erbB*-like DNA in fishes, 50:45
- of T-cell receptor, 44:47; 46:281
- PCR in somatic cell hybrids, 45:217
- RFLP studies in chondrosarcoma, 45:207
- RFLP studies in neurinomas, 45:55
- RFLP studies in teratomas, 46:115
- X-chromosomes, 46:271
- 11q23 in AT, 46:1
- Monosomy**
  - in AILD, 44:77; 50:15
  - in breast cancer, 46:217; 47:107
  - in cervical cancers, 44:229
  - in CIS of testis, 46:75
  - in Hodgkin disease, 50:1
  - in large bowel cancer, 48:83, 107; 46:143
  - in lung tumors, 48:203
  - in lymphoma, 45:125; 47:73
  - in MDS, 46:173
  - in mesothelioma, 47:1
  - in renal cell carcinoma, 45:197
  - in T-ALL, 44:69; 48:229
  - 3 in uveal melanoma, 45:249
  - 5 in CMMoL, 44:131; 46:157
  - 5 in MDS, 45:157; 48:67
  - 5, -7 in secondary leukemia, 48:67
  - 7 in blast crisis (lymphoid), 48:133
  - 7 in CML, 47:197
  - 7 in CMMoL, 44:131; 46:157
  - 7 in male breast cancer, 47:107
  - 7 in MDS, 44:15; 46:125, 157; 48:67
  - 7 in MPD, 49:57
  - 7 syndrome in children, 44:263
  - 10, -22, -X, -Y in gliomas, 47:141
  - 22 in meningioma, 45:237
  - 22 in neurinomas, 45:55
- Monosomy 7 (-7) syndrome**
  - clinical heterogeneity, 44:263
  - in children and adolescents, 44:263
- Mouse**
  - "dic" in Ehrlich-Lettré tumor, 48:23
  - dms and HSR in transformed cells, 49:75
  - plasmacytoma, 46:93
  - variant (15;16) in plasmacytoma, 46:93
- Multiple myeloma**
  - acute leukemia, 48:67
  - secondary leukemia following melphalan therapy, 48:67
- Myelodysplastic syndromes (MDS)**
  - chromosome changes in, 44:15, 187, 271; 45:73, 193; 46:125, 157, 173, 243; 47:171, 275; 48:49, 169, 279
  - chromosome 17 in, 44:15
  - CMMoL, 44:15, 131; 46:99, 157; 47:171
  - cyropreserved cells, 45:179
  - effects of hematopoietic growth factors, 48:169
  - ETS1 in, 45:73
  - FAB subgroups, 44:15; 46:157, 173
  - leukemic transformation, 44:15
  - MDS vs M6, 49:139
  - molecular studies in, 46:243
  - morphology, course and prognosis, 44:15; 46:157, 173
  - multiple clones, 47:171
  - pseudo-Pelger-Huët, 46:173
  - RA, 44:15; 46:157, 173
  - RAEB, 44:15, 46:125, 157, 173
  - RAEB-t, 44:15; 46:157, 173; 47:171
  - RARS, 44:15; 46:157
  - secondary MDS, 46:173; 48:49, 67
  - sequential chromosome changes, 44:15
  - small vacuolated granulocytes, 46:173
  - spontaneous remission, 46:125
  - survival in, 44:19, 22; 46:173; 47:171
  - t(11;21) in, 46:243
  - therapy-related, 46:173; 48:49
  - thrombocytosis and +19, 44:187
  - translocation in, 46:173; 48:49
  - trisomy 8 (+8) in, 44:15; 47:171
  - unrelated clones, 47:171
  - use of G-CSF, 47:277
  - various cytogenetic techniques, 46:157
  - 5q- in, 44:15; 47:171, 275; 48:49, 279
  - 6p in MDS, 44:271
  - 7 and +8 in RAEB, 46:125
  - 7/7q- in, 44:15
  - 11q23 and ETS1, 45:73
  - 12p- in, 44:15; 47:275
  - +13 in MDS, 48:179
  - +19 and thrombocytosis, 44:187
  - Y in, 44:15
- Myelofibrosis**
  - and essential thrombocytosis, 45:193
  - chromosome changes, 49:57
  - hydroxyurea-treated cases, 49:57
  - Robertsonian translocation, 45:193
  - trisomy 14q in, 49:113
  - +14 in, 49:113

- Myeloma; see Multiple myeloma  
 Myeloproliferative disorders (MPD)  
   chromosomes in, 49:57  
   hydroxyurea-treated cases, 49:57  
   transient +21 in newborn, 48:259  
   +21 (transient), 48:259  
 Myoma; see Leiomyoma
- Nasopharyngeal cancer  
   cell line, 49:31  
   chromosomes in, 49:31  
   cytogenetic characterization, 49:31
- Neurinomas  
   chromosome changes in, 45:55  
   chromosome 22, 45:55  
   in neurofibromatosis, 45:55  
   in von Recklinghausen  
     neurofibromatosis, 45:55  
   karyotypes in, 45:55  
   RFLP studies in, 45:55
- Neuroblastoma  
   aphidicolin and neuroblastoma  
     (parents), 50:35  
   cell line, 45:131  
   fragile sites in patients, 50:35  
   marrow metastasis, 45:131  
   t(1;10)(p32;q24), 45:131
- Neurofibromatosis  
   fibroblasts from (radiosensitivity),  
     47:191  
   from skin and café-au-lait spot, 47:191  
   neurinomas in, 45:55; 47:141  
   peripheral nerve sheath tumors, 45:245;  
     47:141  
   radiosensitivity of fibroblasts from skin  
     and café-au-lait spot, 47:191  
   rhabdomyosarcoma, embryonal, 45:245  
   sarcomas in three generations, 45:245
- Non-disjunction  
   aneuploidy, #21 and, 45:279  
   nature of, 45:277
- Non-Hodgkin lymphoma (NHL); see  
   Lymphoma
- Nucleolar organizing regions (NOR)  
   in lymphocytes, 50:207  
   variants in lymphocytes, 50:207
- Oligodendroglioma  
   chromosomes in, 47:141
- Oncogenes  
   *abl* in Ph<sup>+</sup> acute leukemia and CML,  
     44:143  
   *c-mos* in pleomorphic adenomas of  
     salivary gland, 49:165  
   *c-myc* in T-ALL, 48:229  
   *erbB*-like DNA in fishes, 50:45  
   EST1 in MDS with change at 11q23,  
     45:73; 46:243  
   *ets-1* transposition in acute leukemia  
     with t(11;19), 50:199  
   H-*ets-1* and H-*ras* in MDS, 46:243  
   in bladder cancer, 49:143  
   *myc* in brain tumors, 47:141  
   *ras-p21* in salivary gland tumors, 44:153  
   8q12 and *c-mos*, 49:165
- Oral submucous fibrosis  
   SCE studies in patients, 44:197
- Osteosarcoma  
   chromosome changes, 45:121; 50:125  
   radiation-induced, 50:125  
   secondary, 50:125  
   small cell, 45:121  
   t(11;22) in, 45:121
- Ovary  
   adenocarcinomas 45:223; 48:53, 243;  
     49:95  
   Chinese hamster cell line, 46:231  
   chromosomes in malignant ovarian  
     tumor, 44:223; 45:49, 223; 46:65, 71;  
     48:53, 243; 49:95; 50:189  
   clear cell tumor, 48:243  
   clonal evolution of cancer, 48:53  
   desmoid cyst, 44:223; 49:95  
   DNA studies in tumors, 44:223; 46:115  
   endometrioid carcinomas, 48:243  
   germ cell tumor cell line, 50:67  
   i(5p) in mesodermal tumor, 46:65  
   i(12p) in yolk sac tumor, 45:49  
   Krukenberg tumor, 46:71  
   mesodermal tumor (mixed, malignant),  
     46:65  
   metastatic tumor, 48:53  
   mucinous, 48:243  
   numerical changes in, 49:95  
   RFLP studies in teratomas, 46:115  
   sarcoma, 48:243  
   sclerosing stromal tumor, 49:103  
   squamous cell carcinoma, 48:243; 49:95  
   teratomas, 46:115  
   tumor of, 44:223; 45:49, 223; 46:71, 115;  
     48:53, 243; 49:95, 103; 50:189  
   yolk sac tumor, 44:223  
   1, 3, 6 and 9 in, 45:223  
   9p in cancer, 45:223
- Parathyroid tumors  
   adenoma, 48:225  
   t(1;5) in adenoma, 48:225
- Parotid gland  
   mucoepidermoid tumor, 50:161  
   t(3;8) and del(5q) as sole change in  
     tumor, 50:161
- Peripheral nerve sheath tumors  
   in neurofibromatosis (familial), 45:245
- Philadelphia (Ph) chromosomes  
   disappearance in APL in relapse, 47:41



- in a child with Ph+ CML, 44:277
- in acute leukemia, 44:143; 48:35
- in ALL, 48:35; 49:1
- in APL (M3), 47:41
- in blastic phase, 47:219; 50:109
- in CML, 44:143, 181; 46:83; 47:197; 48:75, 209; 50:109
- late appearing in ALL, 48:35
- masked, 47:219
- molecular studies, 44:143, 277; 47:219; 48:75, 209
- variant, 44:181; 46:83; 47:197, 219; 48:209; 50:109
- Pineal tumor
  - germ cell tumor without i(12p), 50:153
- Plasma cell leukemia (PCL)
  - chromosomes in, 47:47
  - ring chromosomes in, 47:47
- Plasmacytoma
  - chromosomes in, 46:93
  - mouse, 46:93
- Pleomorphic adenomas; see Salivary gland tumors
- Plexiform fibrohistiocytic tumor
  - cytogenetics, 48:31
- Polycythemia vera (PV)
  - ANLL in, 44:275
  - t(3;21) and AML in, 44:275
- Polymerase chain reaction (PCR)
  - chromosome mapping, 45:217
  - on somatic cell hybrids, 45:217
- Polyposis coli
  - chromosome changes, 49:249
  - high-resolution karyotypes in patients, 47:69
  - Norwegian cases, 47:69
  - tetraploidy in fibroblasts, 50:139
- Preleukemia; also see Myelodysplastic syndromes
  - chromosomes in, 49:15, 57
  - der(13) in, 49:15
  - molecular studies in, 49:15
  - retinoblastoma gene locus, 49:15
- Prematurely condensed chromosomes (PCC); see Prophasing
- Prophasing
  - acrocentric prophasing with BrdU, 50:269
  - in lymphocytes, 50:269
  - in patients with malignancy, 50:269
- Prostate
  - cytogenetic analysis, 46:191, 48:83
  - technique for culture of cancer cells, 46:191
  - +7, -9 in, 48:83
- Radiation exposure or therapy
  - chromosome abnormalities in, 45:13
  - effects of X-ray on Askin tumor, 47:89
  - effects on bone marrow, 45:13
  - effects on peripheral lymphocytes, 45:13
  - follow-up studies, 45:13
  - in Japan, 45:13
  - radiosensitivity of fibroblasts in NF, 47:191
  - radon-induced M4?, 48:125
  - relation to leukemia, 45:13
  - secondary (radiation-induced) sarcomas, 50:125
  - translocations and, 45:13
- Radon exposure
  - acute leukemia, 48:125
  - secondary M4 after 21 years, 48:125
- Rat
  - chromosome analysis of sarcoma, 50:75
  - Hirosaki sarcoma, 50:75
  - single cell transplantation, 50:75
- Receptors
  - EGFR in melanoma cell line, 46:261
  - TCR and t(7;14) in Sézary syndrome, 46:281
  - TCRA in T-ALL, 44:47; 49:69
- Rectosigmoid tumors; see Large bowel
- Refractory anemia (RA)
  - chromosome changes in, 44:15; 45:73; 46:157, 173; 48:67
  - ETS1 in, 45:73
  - i(14q) in, 49:113
  - prognostic and survival aspects, 44:15; 46:173
  - secondary (therapy-related), 46:173; 48:67
  - 11q23 in, 45:73
- Refractory anemia with excess blasts (RAEB)
  - chromosomes in, 44:15; 45:73; 46:125, 157, 173; 48:67
  - ETS1 in, 45:73
  - multiple clones, 47:171
  - prognostic and survival aspects, 44:15; 46:125, 173
  - secondary (therapy-related) 46:173; 48:67
  - spontaneous remission, 46:125
  - thrombocytosis and +19, 44:187
  - unrelated clones, 47:171
  - 7 and +8 in, 46:125
  - 11q23 in, 45:73
  - +13 in, 48:179
  - +14 in, 49:113
  - +19 in, 44:187
- Refractory anemia with excess blasts in transformation (RAEB-t)
  - chromosomes in, 44:15; 45:73; 46:157, 173
  - ETS1 in, 45:73

- multiple clones, 47:171
- prognostic and survival aspects, 44:15; 46:173
- secondary (therapy-related), 46:173
- unrelated clones, 47:171
- 11q23 in, 45:73
- Refractory anemia with ring sideroblasts (RARS)
  - chromosome changes in, 44:15; 46:157
  - prognostic and survival aspects, 44:15
  - 6p in RARS, 44:271
- Renal tumors; see Kidney
- Ring chromosomes
  - in breast cancer, 49:203
  - in dermatofibrosarcoma, 49:199, 273
  - in medullary thyroid cancer, 47:227
  - in plasma cell leukemia, 47:47
- Retinoblastoma
  - EM detection of deletion, 48:265
  - hereditary, 48:265
  - locus in leukemia and preleukemia, 49:15
  - subband deletion at 13q14.11, 48:265
  - 13q14.11 in, 48:265
- Rhabdomyosarcoma
  - embryonal in neurofibromatosis, 45:245
- Robertsonian translocations
  - in hematologic malignancy, 45:193
  - in leukemia, 45:193
  - in MDS, 45:193
- Salivary gland tumors
  - adenolymphoma, 46:35
  - benign tumors, 44:153, 253; 46:35, 55
  - carcinoma arising in a pleomorphic adenoma, 44:253
  - cell line, 44:253; 46:55
  - chromosome changes in, 44:153, 253; 46:35, 55; 50:161
  - c-mos in adenomas, 49:165
  - malignant tumors, 44:153, 253
  - molecular studies in, 44:153
  - mucoepidermoid tumor of parotid, 50:161
  - pleomorphic adenomas, 46:55
  - t(3;8) and del(5q) as only changes, 50:161
  - tumors, 44:153, 253; 46:35, 55; 50:161
  - Warthin's tumor, 46:35
  - 8q12 and c-mos, 49:165
- Sarcoma
  - chondrosarcoma, myxoid, 45:207
  - chromosomes in, 44:27; 49:199; 50:125
  - dermatofibrosarcoma, 49:199, 273
  - embryonal rhabdomyosarcoma, 45:245
  - Ewing sarcoma, skeletal, 47:61, 89
  - fibrosarcoma, 48:193; 49:199
  - Hirosaki sarcoma (rat), 50:75
  - in neurofibromatosis (three generations), 45:245
  - leiomyosarcoma, 48:217
  - leiomyosarcoma of uterus, 47:89
  - osteosarcoma, 45:121; 47:89; 50:125
  - ovarian, 48:243
  - peripheral nerve sheath tumor, 45:245
  - radiation-induced, 50:125
  - secondary, 50:125
  - spindle cell, 50:125
  - synovial, 50:125
  - uterine, 44:27; 47:89
- Secondary leukemia; also see ANLL
  - chromosomes changes in, 44:275; 45:1; 46:173; 49:57; 50:165
  - following melphalan therapy, 48:67
  - following radon (21 years), 48:125
  - hydroxyurea-therapy of MPD, 49:57
  - in children, 45:1
  - in multiple myeloma, 48:67
  - M1, M2 and M6, 48:67
  - M4 and M5, 45:1
  - previous chemotherapy, 45:1; 46:173; 48:67
  - pseudo-Pelger-Huët in, 46:173
  - secondary APL (M3), 47:41
  - t(1;3) in M4, 50:165
  - t(3;21) in AML secondary to PV, 44:175
  - translocations in, 44:275; 45:1; 46:173; 47:41; 49:57
  - 11q23 anomalies in, 45:1
  - 17p in, 46:173
- Sézary syndrome
  - chromosome studies in a patient, 44:193; 45:231; 46:281
  - cytogenetic follow-up, 45:231
  - lymphocytes and chromosomes, 44:193; 45:231
  - t(7;14) and TCR, 46:281
  - TCR in, 46:281
- Sister chromatid exchange (SCE)
  - at Xq27.3 fragile site, 49:87
  - cancer risk, 45:85
  - in Bloom syndrome, 50:175
  - in lymphocytes, 45:85
  - in patients with oral submucous fibrosis, 44:197
  - no effect of EMS at Xq27.3, 49:87
  - synergistic effects of azathioprine and UV, 45:93
  - trans-acting factors and, 48:89
- Soft tissue tumors
  - chromosome changes in, 50:125
  - fibrosarcoma, 48:193
  - leiomyoma, 44:1; 45:63; 47:95, 179
  - leiomyosarcoma, 48:217
  - lipoma, 45:81; 47:113
  - MFH, 50:125

- plexiform fibrohistiocytic tumor, 48:31
- secondary, 50:125
- spindle cell, 50:125
- synovial sarcoma, 50:125, 277
- Sperm
  - chromosomes in, 46:251
  - effects of cancer treatment, 46:251
- Squamous cell carcinoma
  - chromosome changes in, 44:209; 47:131; 49:37
  - of head and neck, 47:131
  - of larynx, 44:209
  - of lung, 49:37, 185
  - ovarian, 48:243
  - translocations in, 47:131
- Synovial sarcoma
  - chromosomes in, 50:125, 277
  - endonuclease digestion studies, 50:277
  - secondary (radiation-induced), 50:125
  - t(X;18), 50:277
- T-cell
  - ALL (chromosome changes), 44:69; 45:137; 48:229; 49:1, 69, 241
  - ALL with t(14;14)(q11.2;q32), 44:47
  - breakpoints in ALL with t(14;14), 44:47
  - chromosome changes in peripheral T-cell lymphoma, 48:39
  - CLL, 48:39
  - family study of HTLV-I carriers; 49:157
  - HTLV-I carriers; cytogenetic study, 49:157
  - lymphocyte chromosomes in HTLV-I, 49:157
  - lymphoma, 48:39
  - receptor alpha chain, 44:47
  - Sézary syndrome, 44:193; 46:281
  - t(8;11)(q24;q11), 49:69
  - T-ALL cell line with t(16;20); 49:241
  - 6q- in ALL, 48:229
- Techniques
  - G-CSF in myeloid leukemias and MDS, 47:277
- Telomere
  - no sequences in dms, 48:271
- Teratoma
  - benign, 46:115
  - chromosomes in, 46:115
  - of ovary, 46:115
  - origin of, 46:115
  - RFLP zygosity, 46:115
- Testis
  - adult tumors, 48:143
  - autosomal dosage, 48:1
  - cell lines, 50:67
  - chromosome changes in, 46:75; 48:1, 143; 50:67
  - CIS of, 46:75
  - cytogenetic model, 48:143
  - germ cell tumors, 48:143; 50:67
  - i(12p) in, 46:75; 48:1, 143; 50:67
  - molecular studies in tumors, 48:1
  - pathogenesis, 48:143
  - seminoma, 48:1, 143
  - teratocarcinoma, 48:1
  - tumor of, 46:75; 48:1, 143; 50:67
  - yolk sac tumor, 48:143
- Therapy-related ANLL and MDS; see Secondary leukemia
- Thorotrast
  - effects on chromosomes, 45:13
  - Y, 45:13
- Thrombocytosis
  - +19 in MDS with, 44:187
- Thyroid
  - adenomas, follicular, 44:119, 217
  - chromosomes in tumors, 44:119, 127 (Table), 217; 47:227; 50:249
  - DNA content, karyotypes and clinical data, 50:249
  - follicular adenomas, 44:119, 217; 50:249
  - hypodiploid, pseudodiploid and normal karyotypes in medullary cancer, 47:227
  - medullary carcinoma, 47:227; 50:249
  - metastatic cancer, 47:227
  - oxyphil cell adenoma, 50:249
  - papillary cancers, 44:119; 50:249
  - 1 and 11 in tumors, 44:119
- Transient changes
  - MPD with +21 (transient), 48:259
  - +21 in newborns, 48:259
- Translocations
  - in AILD, 50:15
  - in ALL, 44:143; 46:201; 49:1; 50:31
  - in AML, 44:169, 47:139
  - in ANLL, 44:99, 143, 169; 45:1, 67; 46:99, 173; 47:139; 48:255
  - in APL, 47:41
  - in Askin tumor, 47:89
  - in breast cancer, 46:217; 47:107
  - in cervical cancers, 44:229
  - in CIS of testis, 46:75
  - in CML, 46:83; 47:55, 197; 48:75, 209
  - in CMMoL, 46:99
  - in endometrial tumors, 46:41
  - in Ewing sarcoma, 47:61, 89
  - in Hodgkin disease, 50:1
  - in large bowel cancers, 44:83; 46:143
  - in leiomyosarcoma, 48:217
  - in lipoma, 45:81; 47:113
  - in lung tumors, 48:203
  - in lymphoma, 45:125; 47:73; 48:199
  - in MDS, 46:157, 173, 243
  - in meningioma, 45:237
  - in mesotheliomas, 47:1



- in myoma, 44:1; 49:51  
 in M4, 44:99; 45:261; 48:255  
 in M7, 48:119  
 in osteosarcoma, 45:121  
 in radiation exposure, 45:13  
 in radiation-induced sarcomas, 50:125  
 in salivary gland tumors, 44:153; 46:55  
 in squamous cell carcinoma, 44:209; 47:131  
 in T-ALL, 44:69; 49:1; 50:31  
 in tuberous sclerosis, 45:161  
 in uterine tumors, 46:41  
 in Wilms tumor (X;20), 45:35  
 Philadelphia chromosome, 44:143, 181  
 Robertsonian, 45:193  
 (?;5)(5;21)(?;q35p11;q11) in subcutaneous leiomyosarcoma of the knee, 48:217, 220  
 (?;14)(?;q12→q22::q24→qter) c-myc gene in T-cell malignancies, 48:233  
 (?;16)(?;q12.2) c-myc gene in T-cell malignancies, 48:232  
 (X;?)(p11;?) B cell growth factor (BCGF) and lymphoma cytogenetics, 48:111  
 (X;?)(p22;?) in NHL, 47:78  
 (X;?)(Xqter→Xp22::?) in male breast cancer, 47:108  
 (X;1)(q22;p13) in a thyroid carcinoma, 50:256  
 (X;1;13)(Xpter→Xq23::1p36.2→1pter;1qter→1p31.3::13q33→13qter;13pter→13q33::1p31.3→1p36.2::Xq23→Xqter) in neurinoma, 45:57–58  
 (X;3)(p11;p21) in de novo MDS, 44:21  
 (X;6)(p22;q21) in benign uterine leiomyoma, 44:4  
 (X;7)(q11;q36) in NHL, 47:78  
 (X;9;11;22)(p11;q34;q12;q11) atypical Ph+ CML, 44:181, 182, 184–185  
 (X;9;22)(q11;q22;q12) atypical Ph+ CML, 44:185  
 (X;9;22)(q27;q34;q12) atypical Ph+ CML, 44:185  
 (X;10)(q13;p11-12) in adenolymphoma, 46:37  
 (X;10)(q13;q26) in human malignant melanoma (HMM), 48:238–239  
 (X;10)(q22q23;q24) in an ependymoma, 49:237  
 (X;11) in salivary gland pleomorphic adenoma (PSA), 46:60  
 (X;11)(q26;q21) in colorectal tumor, 44:93  
 (X;11)(Xpter→Xq26::11q23→11qter;11pter→ataxia-telangiectasia (A-T) gene locus, 46:1–3, 5  
 (Xq11q) in breast cancer, 49:205  
 (X;12)(p22.3;q15) in uterine leiomyoma, 49:54, 237  
 (X;12)(q27;q14) in a lipoma, 49:235–237  
 (X;14) mapped in T-cell ALL, 44:50, 51  
 (X;18) in soft tissue sarcoma, 50:126, 132  
 (X;18) in synovial sarcoma, 50:277–278  
 (X;18)(p11;q11) in fibrosarcoma, 48:196–197  
 (X;18)(p11.2;q11.2) in synovial sarcoma, 49:237; 50:277–278  
 (X;19)(q22;q13.1) in thyroid adenoma, 50:254  
 (X;20)(q11;q11) in a child with Wilms tumor associated with Wiedemann-Beckwith syndrome, 45:35, 36–38  
 (X;22)(p22;q11) atypical Ph+ CML, 44:185  
 (X;22)(q28;q11) atypical Ph+ CML, 44:181, 182, 185  
 (Y;1)(q12;q21) in B-cell lymphoma, 49:221–222  
 (Y;4)(q12;q21) in adenolymphoma, 46:37  
 (Y;12) in salivary gland pleomorphic adenoma (PSA), 46:60  
 (Y;15)(q12;q14 or q15) in malignant mesothelioma (MM), 47:11, 14, 23  
 (1;?) in bladder carcinoma, 49:145  
 (1;?) in NHL with del(7)(p14), 50:55  
 (1p?) in esophageal carcinoma cell line, 45:111  
 (1;?)(p32;?) in hepatocellular carcinoma, 45:259  
 (1;?)(p34;?) in NHL, 47:78  
 (1;?)(p36;?) in malignant mixed mesodermal tumor of ovary, 46:65, 67  
 (1;?)(p36;?) in NHL, 47:78  
 (1;?)(q?11;?) B cell growth factor (BCGF) and lymphoma cytogenetics, 48:111  
 (1;?)(q21;?) in de novo MDS, 44:21  
 (1;?)(q25;?) in carcinoma of the cervix uteri, 44:230  
 (1;?)(q42;?) in MDS and ANLL, 46:178  
 (1;?)(q42;?) in NHL, 47:78  
 (1;?)(1qter→1q11::?) marker chromosome in a rare pineal region mixed germ tumor, 50:156–157  
 (1;1) in neuroblastoma, 45:134  
 (1;1) in thyroid tumor, 44:127  
 (1;1)(p32;q21) in neuroblastoma cell line, 45:131  
 (1;1)(p32;q25) in NHL, 47:78  
 (1;1)(p32;q32) in uterine leiomyosarcoma, 48:217, 220–221  
 (1;1;15)(q21;p12;p13) in SCC of the larynx, 44:211  
 (1;2)(p33;q24) in thyroid tumor, 44:127  
 (1;2)(p33;q34) in ANLL in relapse, 44:174

- (1;2)(p36;p24) in benign uterine leiomyoma, 44:10; 47:97
- (1;2)(q22;q33) in adenocarcinoma of the prostate, 48:86
- (1;2)(q44;q31) from radiation-induced tumors, 50:128
- (1;2;17)(p13;p12;q24) in esophageal carcinoma cell line, 45:105-106
- (1;3) in MDS, 46:158
- (1;3) in NHL with del(7)(p11p15), 50:55
- (1;3)(p11;q11) in esophageal carcinoma cell line, 45:107
- (1;3)(p12;q21) from radiation-induced tumors, 50:128
- (1;3)(p32-p34;q27-q29) in angiofibroma, 45:168
- (1;3)(p33;p21) RCC, 45:199
- (1;3)(p33;q26) in T-cell ALL, 44:70
- (1;3)(p36;q21) before and after BMT, 47:258
- (1;3)(p36;q21) with -7 in M4 ANLL secondary to multiple myeloma, 50:165-167
- (1;3)(q11;p11) in esophageal carcinoma cell line, 45:107
- (1;3)(q21;q29) in endometrial adenocarcinoma, 46:42-45, 50
- (1;3)(q23;q23) in lipoma, 47:116-117, 120, 127
- (1;3)(q23 or q25;q29) in Ph+ CML BC, 47:198, 200, 211
- (1;3)(q44;p12) in SCC of the larynx, 44:211, 213, 215
- (1;3;2)(p32;p21;q37) in uterine sarcoma, 44:32, 33
- (1;3;5;9;22) masked Ph in CML, 47:223
- (1;3;6)(p36;q21;p21) in a lipoma, 45:83
- (1;3;8)(p22;p21;q12) in pleomorphic adenoma (PSA), 49:166
- (1;4) in breast cancer, 46:217
- (1;4)(1pter>1p22::4p14>4qter) in male breast cancer, 47:108
- (1;4)(p22;q28) in SCC of the larynx, 44:211, 212, 215
- (1;4)(q21;q21) in human malignant melanoma (HMM), 48:240-241
- (1;5) in a child with CML, 46:86-87
- (1;5) in breast cancer, 46:217
- (1;5)(p13;q12) in endometrial adenocarcinoma, 46:50
- (1;5)(p14;q13) in de novo MDS, 44:21
- (1;5)(p22;q32) in parathyroid adenoma, 48:225, 227-228
- (1;5)(q21;p15) in PLL, 48:184
- (1;5)(q21 or q22;q31) in Ph+ CML in CP, 47:204, 207, 211
- (1;5)(q25;p15) in SCC of the larynx, 44:211, 213
- (1;5)(q43;q12) in ANLL, 44:173
- (1;6) in bladder carcinoma, 49:145
- (1;6)(p12;p23) in ANLL, 45:67
- (1;6)(p13;p21.3) in ANLL, 45:68-69
- (1;6)(p13;p23) in ANLL evolving from MDS, 45:67, 69
- (1;6)(q24;p22) in benign lipoma, 48:281-282
- (1;6)(q32;p21) in uterine sarcoma, 44:32, 33
- (1;6)(q42;p23) in adenolymphoma, 46:37
- (1;7) in breast cancer, 49:206
- (1;7) in exposure to cytotoxic substances in t-MDS, 46:170
- (1;7) in t-MDS, 46:158, 170
- (1;7)(p11;p11) in hematologic disorders, 45:67, 69; 48:51
- (1;7)(p11;p11) in RA, 46:163
- (1;7)(p31;q35) in breast cancer, 49:213
- (1;7)(p32;p22) after radiation therapy in Askin's tumor, 47:90-92
- (1;7)(p32;q34) in a thyroid carcinoma, 50:255-256
- (1;7)(q12;p22) in radio- or chemotherapy treated sperm, 46:255
- (1;7)(q21-q23;q32-q36) in angiofibroma, 45:168, 170
- (1;7;14)(q25;q32;q22) in meningioma, 45:239
- (1;8)(p11;q11) in childhood erythroleukemia, 49:28
- (1;8)(p22;q12) in pleomorphic adenoma (PSA), 49:166
- (1;8)(q32;q21) Ph+ cells in unstimulated PB, 47:261
- (1;8)(q32;q21) Ph- cells in unstimulated PB after second BMT, 47:261
- (1;9) in lipoma, 47:116, 121, 125
- (1;9)(p11;p13) in RCC, 45:199
- (1;9)(p11;q11) in nasopharyngeal carcinoma, 49:32-33
- (1;9)(p13;p13) in breast cancer, 46:224
- (1;9)(p22;q31) in human malignant melanoma (HMM), 48:240-241
- (1;9)(p22;q34) in SCC of the larynx, 44:215
- (1;9)(p31;q21) in angioimmunoblastic lymphadenopathy (AILD), 50:22
- (1p9q) in breast cancer, 49:205-206, 208
- (1;9)(q11;p21) in angioimmunoblastic lymphadenopathy (AILD), 50:19
- (1;9)(q12;q13) in CMMoL, 46:99, 101-104
- (1;9)(q23;p13) in childhood pre-B ALL, 46:201, 205-207
- (1;9)(q23-25;p22-21) in ALL, 45:125, 128
- (1;9)(q47;q13) in endometrial adenocarcinoma, 46:42-43, 45, 50
- (1;9)(q43;q21) in mixed mesodermal tumor of ovary, 46:65, 67

- (1;10)(p12;q22.3) from radiation-induced tumors, 50:128
- (1;10)(p32;q24) in neuroblastoma cell line, 45:131, 133–134
- (1;11)(p12;q24) in diffuse large cell NHL, 50:54
- (1;11)(p21;p12) in esophageal carcinoma cell line, 45:103
- (1;11)(p21;q25) in uterine sarcoma, 44:32, 33
- (1;11)(p32;p15) in neuroblastoma cell line, 45:131
- (1;11)(p32;q23) in ALL, 49:3
- (1;11)(q21 or q23;p15) in Ph+ CML in BC, 47:200, 211
- (1;11;4)(q31;q13.1;p16) in Sézary syndrome, 44:194
- (1;11;12)(1pter→1q21::12q13→12qter;1qter→1q21::11p13→11qter;12pter→12q13::11p13→11pter) with congenital anomalies in progeny of a mother treated for childhood leukemia, 50:169–170
- (1;12) in lipoma, 47:127
- (1;12) in mixed and myxoid liposarcoma, 48:104
- (1;12)(p22;p13) in childhood erythroleukemia, 49:28
- (1;12)(12qter→12p11.2::1p13→1p34:) in male breast cancer, 47:108
- (1;12)(q21;q13) in salivary gland pleomorphic adenoma (PSA), 46:57
- (1;12)(q43;q14) in uterine leiomyoma, 49:53–54
- (1;13) in neuroblastoma, 45:134
- (1;13)(p36;q14) in MDS, 49:114–116
- (1;14)(p13;q11?) in angioimmunoblastic lymphadenopathy (AILD), 50:19, 22
- (1;14)(p32;q11) in T-cell ALL, 44:70, 72
- (1;14)(q23;q32) in T-cell ALL, 44:70
- (1;15) in acute megakaryoblastic leukemia (ANLL-M7), 48:122
- (1;15) in endometrial adenocarcinoma, 46:45
- (1;15)(p36;q15) in benign uterine leiomyoma, 44:5
- (1;15)(p36.1;q11.2) from radiation-induced tumors, 50:128
- (1;15)(q12;p11) in RA, 46:160, 163, 166, 169
- (1;15)(q34;q21) in ALL, 46:111
- (1;16) in endometrial adenocarcinoma, 46:45
- (1;16) in Ewing sarcoma, 45:9
- (1;16)(p32;p12) in ANLL, 44:173
- (1;16)(q11;q11) in a thyroid adenoma, 50:256
- (1q16p) in breast cancer, 49:204, 206–207, 210–211, 213
- (1;17) in PCL, 47:52
- (1;17)(p12;p11) in RA, 44:23
- (1;17)(q31 or q32;p11) in Ph+ CML in CP, 47:202–204, 210
- (1;18)(p31;q23) in SCC of the larynx, 44:211–212
- (1;18)(p32;q12) in a thyroid adenoma, 50:256
- (1;18)(p32;q12.1) in a thyroid adenoma, 50:255
- (1;18)(p36;q22) in T-ALL, 50:31
- (1;18)(:1p35→1p13::18p11.2→18qter) in male breast cancer, 47:108
- (1;19) in childhood ALL, 49:4
- (1;19) poor-risk subgroup in ALL, 49:8
- (1;19)(p21;p13) in de novo MDS, 44:21
- (1;19)(q23;p13) in childhood pre-B ALL, 46:201, 205–207
- (1;19)(q23;p13) in pre-B cell ALL, 44:69; 45:183–184
- (1;19)(q23;p13.3) in ALL, 49:3
- (1;19)(q31;qter) in breast cancer, 49:205
- (1q21q) in breast cancer, 49:206, 210, 213
- (1;22) in endometrial adenocarcinoma, 46:45, 51
- (1;22)(p32;q12) in breast cancer, 49:204, 206, 213
- (1;22)(q32;q13) in fibrosarcoma, 48:196
- (1q22q) in breast cancer, 49:213
- (1;22;9)(p32;q11;q34) masked Ph in CP and BP of CML, 47:219, 221–223
- (2;?) in thyroid tumor, 44:127
- (2;?)(p13;?) in Sézary syndrome, 45:235
- (2;?)(p21;?) in Hodgkin's disease (HD), 50:7
- (2;?)(p21;?) in NHL, 47:78
- (2;?)(p24;?) in NHL, 47:78
- (2;?)(p25;?) in mixed mesodermal tumor of ovary, 46:65, 67
- (2;?)(q37;?) in Hodgkin disease (HD), 50:3
- (2;2)(p15;q21) in esophageal carcinoma cell line, 45:106, 112
- (2;3) in NHL with del(7)(p11p15), 50:55
- (2;3)(p23;p21) in patients administered Thorotrast, 45:22–23
- (2;3)(q11;qter) in NHL, 47:78
- (2;3)(q12;p24) in a thyroid adenoma, 50:256
- (2;3)(q33;p21) in nasopharyngeal carcinoma, 49:32–33
- (2;4) in a SV40 virus-transformed tumorigenic human cell line, 50:231
- (2p4q) in a SV40 virus-transformed tumorigenic human cell line, 50:239, 242–243, 245



- (2;4;19) DMS and +7 in BC of CML, 48:133-134
- (2;5)(p23;p15) after radiation therapy in Askin's tumor, 47:90, 92
- (2;5)(q21;q33) in SCC of the larynx, 44:211, 213, 215
- (2;5)(q37;q32) in angioimmunoblastic lymphadenopathy (AILD), 50:19
- (2;5;5;10;12) in lipoma, 47:115-117
- (2;5;9)(p11;q13;p24) in SCC of the larynx, 44:211
- (2;6)(p23;q21) in SCC of the head and neck, 47:131-133
- (2;6)(q21;q21) in peripheral T-cell lymphoma (PTCL), 48:42
- (2;6)(q36;p21.3) in a lipoma, 45:81-82
- (2;6)(q36;q23) in NHL, 47:78
- (2;7)(q21;p22) as a primary change in M5 ANLL, 49:278
- (2;7;14)(q23;q36;q22) in meningioma, 45:239
- (2;8) in Burkitt lymphoma, 46:93
- (2;8) poor-risk subgroup in ALL, 49:8
- (2;8)(p12;q24) IGK and MYC in B-ALL, 49:6
- (2;8)(p12;q24) in B-ALL, 49:3
- (2;8)(p12;q24) in Burkitt lymphoma, 49:72
- (2;8)(p13;q24) from radiation-induced tumors, 50:128
- (2;8)(q13 or q14;q24.1) in B-cell lymphoma, 49:219, 222
- (2;9)(p12;q13) in a thyroid adenoma, 50:256
- (2;9)(q13;q34) in SCC of the larynx, 44:215
- (2;9;22)(p15 or p13;q34;q11) variant in CML, 47:199
- (2;11)(p15;q13) from radiation-induced tumors, 50:128
- (2;11)(p21;q23) in MDS, 45:73; 46:158; 163, 170
- (2;11)(q21;q11) in human malignant melanoma (HMM), 48:240-241
- (2;11;19)(q22;p13;q13.3) in a prostatic tumor, 48:221
- (2;12)(p11.2;p13) in childhood erythroleukemia, 49:28
- (2;12)(p12;q13) in Sézary syndrome, 45:235
- (2;12)(q11;p13) normal karyotype in leukemic cells before BMT, 47:254
- (2;12)(q21;q24) in adenolymphoma, 46:37
- (2;12)(q37;q14) in uterine leiomyoma, 49:54
- (2;13)(q23;q14) in radio- or chemotherapy treated sperm, 46:255
- (2;13)(q37;q14) in rhabdomyoma, 44:33
- (2;13;13)(p22q37;q11;q11) in Sézary syndrome, 45:235
- (2;14) in a SV40 virus-transformed tumorigenic human cell line, 50:231
- (2;14) in NHL with del(7)(p11p15), 50:55
- (2p14q) in a SV40 virus-transformed tumorigenic human cell line, 50:239, 241-245
- (2;14)(p13;q32) in angioimmunoblastic lymphadenopathy (AILD), 50:19
- (2;14)(p13;q22) from radiation-induced tumors, 50:128
- (2;14)(q23;q32.3) in M4 ANLL, 48:255-257
- (2;15)(p11;p11-p13) in angiofibroma, 45:168, 171
- (2;15)(p23 or p25;q15) in Ph+ CML in CP, 47:202-203, 210
- (2;15)(p23;q26) in fibrosarcoma, 48:196
- (2;15)(q11;q15) in Ph+ CML in CP, 47:202, 205
- (2;15)(q31;q15) in childhood erythroleukemia, 49:28
- (2;16)(p11.2;q24) in human malignant melanoma (HMM), 48:240-241
- (2;17)(q21;q21) from radiation-induced tumors, 50:128
- (2;18) in acute megakaryoblastic leukemia (ANLL-M7), 48:119
- (2;18)(q13;q23) in human malignant melanoma (HMM), 48:240-241
- (2;18)(q33;p11) in acute megakaryoblastic leukemia (ANLL-M7), 48:119-121
- (2;21)(p11;q11) in t-MDS progressed to "frank" leukemia, 48:50
- (2;21)(p15;q22) normal karyotype in leukemic cells before BMT, 47:255
- (2;22)(q13;q13) in esophageal carcinoma cell line, 45:103
- (2;22)(q37;q11) variant in CML, 47:199
- (3;?) in a SV40 virus-transformed tumorigenic human cell line, 50:231, 239, 244
- (3;?) in bladder carcinoma, 49:145
- (3;?)(p1?)(p1?) B cell growth factor (BCGF) and lymphoma cytogenetics, 48:111
- (3;?)(p13;?) in MDS and ANLL, 46:178
- (3;?)(p24;?) in NHL, 47:78
- (3;?)(q21;?) in de novo MDS, 44:21
- (3;?)(q26;?) normal karyotype in leukemic cells before BMT, 47:254
- (3;?)(q27;?) in a SV40 virus-transformed tumorigenic human cell line, 50:239, 242-244

- (3;?)(q27 or 29;?) in Hodgkin's disease (HD), 50:7  
 (3;?)(q29;?) in NHL, 47:78; 50:54  
 (3;3) in MDS, 46:166  
 (3;3) in megakaryoblastic crisis of CML, 47:57  
 (3;3)(p25;q29) in erythroleukemia (EL), 50:91-92  
 (3;3)(q21;q26) in RAEB-t, 46:160, 163  
 (3;3)(q28 or 29;p12 or 13) in a SV40 virus-transformed tumorigenic human cell line, 50:243-244, 246  
 (3;4)(p21 or p22;q12) in MDS, 45:75  
 (3;4)(p21;q31) in malignant mesothelioma (MM) 47:11  
 (3;4)(p21;q34) in malignant mesothelioma (MM) 47:27  
 (3;4)(p25;p13) in angioimmunoblastic lymphadenopathy (AILD), 50:19  
 (3;4)(q21;p12) alteration in RB1 gene in leukemia, 49:18  
 (3;4)(q26;q21) growth factors (rhGM-CSF) in MDS, 48:169, 171, 174-175  
 (3;4;8)(p26;p13 or p14;q12) in pleomorphic adenoma (PSA), 49:166  
 (3;4;9;11;22) in CML, 46:87  
 (3;4;9;22)(q27;q31;q22;q11) atypical Ph+ CML, 44:181, 182, 184  
 (3;5)(p25;p15.3) from radiation-induced tumors, 50:128  
 (3;5)(q23;q31) in bladder carcinoma, 49:109  
 (3;5)(q25;q22) in L1 T-cell ALL, 45:137  
 (3;6)(p13;q27) in acute megakaryoblastic leukemia (ANLL-M7), 48:119-122  
 (3;6)(p14;q11) in esophageal carcinoma cell lines, 45:115  
 (3;6;14)(q12;q23;p11) in SCC of the larynx, 44:211, 214  
 (3;7) alteration in RB1 gene in leukemia, 49:18  
 (3;7) in thyroid tumor, 44:127  
 (3;8)(p12;q12) in mixed salivary gland tumor, 36:52  
 (3;8)(p21;q12) in a mucoepidermoid tumor of the parotid gland with del(5)(q22), 50:161-163  
 (3;8)(p21;q12) in pleomorphic adenoma (PSA), 49:166  
 (3;8)(p21;q12) in salivary gland pleomorphic adenoma (PSA), 44:154, 155, 161; 46:55, 58, 60  
 (3;8)(p21 or p23;q12 or q13) in salivary gland pleomorphic adenoma (PSA), 46:60  
 (3;8)(p23;q12) in salivary gland pleomorphic adenoma (PSA), 46:60  
 (3;8)(3qter→3p26::8q12→8qter) in pleomorphic adenoma (PSA), 49:166  
 (3;9)(p11;p11) in childhood erythroleukemia, 49:27  
 (3;9)(p11;p21) in childhood erythroleukemia, 49:28  
 (3;9)(p25;q34) in SCC of the larynx, 44:215  
 (3;9)(q13;p21) in AML, 46:111  
 (3;9)(3qter→3q12::9q12→9pter) in male breast cancer, 47:108  
 (3;9)(q23 or q25;p13 or p21) in salivary gland pleomorphic adenoma (PSA), 46:57  
 (3;9)(q23;p22) in childhood erythroleukemia, 49:27-28  
 (3;10)(q22;q22) in malignant mesothelioma (MM) 47:11, 22  
 (3;10)(q26;q24) in NHL, 47:78  
 (3;11)(q21-q23;p14) in ANLL in relapse, 44:173  
 (3;11)(q25;q13) from radiation-induced tumors, 50:128  
 (3;11)(3qter→3p12::11q13→11qter) in male breast cancer, 47:108  
 (3;12)(p21;q23) in malignant mesothelioma (MM), 47:11, 24  
 (3;12)(3pter→3p12::12p11.2→12qter) in male breast cancer, 47:108  
 (3;12)(q13;p13) in peritoneal mesothelioma, 46:135-136  
 (3;?12)(q25;?q21) in nasopharyngeal carcinoma, 49:32  
 (3;12—(q26;p12) CMMoL in a child, 44:131-136  
 (3;12)(q28;q14) in benign lipoma, 46:52; 47:127  
 (3;13)(q12-q13;q33-q34) in angiofibroma, 45:168-169  
 (3;13)(q13;q34) as a primary change in M5 ANLL, 49:277-278  
 (3;14)(q13;q11) in angioimmunoblastic lymphadenopathy (AILD), 50:19  
 (3;14)(q21;q32) in de novo MDS, 44:21  
 (3;15)(q29;q12) in ANLL, 44:173  
 (3;16)(p21;q24) in human malignant melanoma (HMM), 48:240-241  
 (3;16)(q21;p13) in NHL, 47:78  
 (3;17) in a child with bilateral nephroblastoma, 45:36  
 (3;17)(p11;q11-q12 or q21.1) in MDS, 44:273  
 (3;17)(p11;q25) in children with M4-M5 ANLL, 45:1-2, 6-7  
 (3;17)(p21;p11) in Ph+ CML in CP, 47:202-204, 210  
 (3;17)(q21;q21) in uterine sarcoma, 44:32, 33

- (3;18) in malignant mesothelioma (MM) 47:16, 27  
(3;18)(p14;p11) in malignant mesothelioma (MM) 47:11, 27  
(3;19)(p11;q11) in nasopharyngeal carcinoma, 49:32  
(3;19)(p21;p12) from radiation-induced tumors, 50:128  
(3;19)(p21;p13) in nasopharyngeal carcinoma, 49:32  
(3;19)(q22;p13) in NHL, 47:78  
(3;20)(p11;p11) in childhood erythroleukemia, 49:27  
(3;20)(q21;p13) in NHL, 47:78  
(3;21)(p14;q22) in M2 ANLL, 45:28  
(3;21)(q25;p11) in essential thrombocythemia (ET), 49:60  
(3;21)(q26;q22) in AML secondary to PV, 44:275-276  
(3;21)(q26;q22) in CMMoL secondary to epithelioid hemangioendothelioma, 50:227-229  
(3;21)(q26;q22) in patient with a solid tumor, 50:227  
(3;21)(q26;q22) in Ph+ CML, 50:227, 229  
(3;21)(q26;q22) In Ph+ CML blast phase, 47:55-58; 50:227  
(3;21)(q26;q22) in Ph+ CML chronic phase, 50:227  
(3;21)(q26-27;q22) in ANLL, 44:99, 101-104  
(3;22)(q28;q11) atypical Ph+ CML, 44:181-183  
(4;?)(p1;?) B cell growth factor (BCGF) and lymphoma cytogenetics, 48:111  
(4;?)(p15;?) in adenolymphoma, 46:37  
(4;?)(p15;?) in nasopharyngeal carcinoma, 49:32  
(4;?)(p15.2;?) in Sézary syndrome, 45:235  
(4;?)(p16;?) in NHL, 47:78  
(4;4) in thyroid tumor, 44:127  
(4;5)(q21;q33) from radiation-induced tumors, 50:128  
(4;6)(q31;p23) in a lipoma, 45:82  
(4q6p) in breast cancer, 49:205  
(4;6;13)(p16;q14;q13) in malignant mesothelioma (MM), 47:11, 23  
(4;7)(q21;q36) in uterine sarcoma, 44:32, 33  
(4;7)(q35;p21) in a thyroid adenoma, 50:256  
(4;8)(p16.1;q11.2) in peripheral T-cell lymphoma (PTCL), 48:42  
(4;8)(4pter→4p14::8q12→8pter) in pleomorphic adenoma (PSA), 49:166  
(4;8)(q13;p12) in ANLL, 44:173  
(4;8)(q21;q22) from radiation-induced tumors, 50:128  
(4;8)(q21;q22) in angioimmunoblastic lymphadenopathy (AILD), 50:19  
(4;9)(p12;q11) alteration in RB1 gene in leukemia, 49:18  
(4;9)(p12;q34) from radiation-induced tumors, 50:128  
(4;9)(q21;q34) in childhood erythroleukemia, 49:28  
(4;10)(p11;q11) or (q11;p11) in malignant mesothelioma (MM) 47:11, 23  
(4;10)(p15;q21) in malignant mesothelioma (MM) 47:24  
(4;10)(q21;p15) in human malignant melanoma (HMM) 48:240-241  
(4;10)(q24;q23) in malignant mesothelioma (MM) 47:11, 21  
(4;11) and disease-free survival in ALL, 49:9  
(4;11) and poor-risk subgroup in ALL, 49:8, 246  
(4;11) in ALL, 44:57, 58; 46:248; 49:134  
(4;11) in childhood ALL, 49:4  
(4;11) in t-MDS, 49:135  
(?4;11) in thyroid tumor, 44:127  
(4;11)(p15;q25) in angioimmunoblastic lymphadenopathy (AILD), 50:19  
(4;11)(q21;q23) and ataxia-telangiectasia (A-T) gene locus, 46:1-6  
(4;11)(q21;q23) and carcinogen exposure in ALL, 49:133-135  
(4;11)(q21;q23) in ALL, 44:69, 73; 49:3, 133-134  
(4;11)(q21;q23) in children with M4-M5 ANLL, 45:1-2, 6-8  
(4;11)(q21;q23) transposition of *ets-1* in AL, 50:199, 201  
(4;11)(q31;q13) in malignant melanoma, 44:63, 64  
(4;12)(q21;p13) in NHL, 47:78  
(4;13)(q12;q12) in childhood erythroleukemia, 49:28  
(4;13)(q21;q32) in childhood erythroleukemia, 49:28  
(4;14)(p16;q22-q24) in angiofibroma, 45:168-169  
(4;14)(q25;q32) from in vitro radioresistance, 50:132  
(4;16)(q11 or q12;p13) in Ph- CML, 47:205-206, 213  
(4;17)(q13;p13) in uterine sarcoma, 44:32, 33  
(4;18) polyploidization in colorectal adenocarcinoma, 44:110  
(4;18;13;9;22)(q12;q11;q14;q34;q11) in a child with CML, 46:85



- (4;22)(p;q) in fibrosarcoma, 48:196  
 (4q22q) in breast cancer, 49:205  
 (5;?)(p;?) in fibrosarcoma, 48:196  
 (5;?)(p15;?) in fibrosarcoma, 48:196  
 (5;?)(q33;?) TCR rearrangement in Sézary syndrome, 46:281–282  
 (5;?)(q34;?) in hepatocellular carcinoma, 45:259  
 (5;?)(q35;?) in SCC of the larynx, 44:211–212  
 (5;5)(p15;q31) in CML blast phase, 47:56  
 (5;6)(q31;p23) from radiation-induced tumors, 50:128  
 (5;6)(q35;q15) in angiofibroma, 45:168–169  
 (5;7)(q11;p11) in malignant myeloid disorders, 48:50  
 (5;7)(q31;q11) in CML, 46:85  
 (5;8)(q12;q11;p11) in SCC of the larynx, 44:211, 214  
 (5;8;21)(q22;q22;q31) in ANLL, 44:173  
 (5;9)(q12;q33) RCC, 45:199  
 (5;9)(q13;q13) from radiation-induced tumors, 50:128  
 (5;9)(q23;q34) from radiation-induced tumors, 50:128  
 (5;9;12;22) in CML, 48:77, 79–80  
 (5;10)(p15.3;q24) from radiation-induced tumors, 50:128  
 (5;11)(p14;q23) in male breast cancer, 47:110  
 (5;11)(q35;p13) in malignant mesothelioma (MM), 47:11, 14, 23  
 (5;11)(q35;q13) in uterine sarcoma, 44:32, 33  
 (5;12)(q13;q24) in childhood erythroleukemia, 49:28  
 (5;12;22) in CML, 48:77, 80  
 (5;13)(q31;q12) in T-cell ALL, 44:70  
 (5;14)(p15.1;q31.2) in radio- or chemotherapy treated sperm, 46:255  
 (5;14)(q24;q32) In ALL, 45:185  
 (5;15)(q11;q11) In RCC, 45:199  
 (5;16)(q11;q24) in synovial sarcoma, 50:277–278  
 (5;17)(p11;p11) in MDS and ANLL, 46:173–175, 178, 180–181  
 (5;17)(q11;p11) in t-MDS, 48:49–50  
 (5;17)(q31;p13) from radiation-induced tumors, 50:128  
 (5;18)(q11.2;q11.2) in synovial sarcoma, 50:277  
 (5;19)(q13;q13) in a thyroid adenoma, 50:256  
 (5;19)(q31;p13.1) from radiation-induced tumors, 50:128  
 (5p21q) in breast cancer, 49:205  
 (6;?)(p11;?) in nasopharyngeal carcinoma, 49:32  
 (6;?)(p22;p23) in nasopharyngeal carcinoma, 49:32  
 (6;?)(p24;?) in angioimmunoblastic lymphadenopathy (AILD), 50:19  
 (6;?)(p24;?) in SCC of the larynx, 44:211–212  
 (6;?)(p25;?) in SCC of the larynx, 44:211–212  
 (6;?)(q25;?) in Hodgkin's disease (HD), 50:2, 4  
 (6;?)(q27;?) in Hodgkin's disease (HD), 50:7  
 (6;?)(6qter→6p23::?) in benign salivary gland pleomorphic adenoma, 44:256  
 (6;?)(6qter→6q13::HSR(?)) in benign salivary gland pleomorphic adenoma, 44:256  
 (6;6) in salivary gland pleomorphic adenoma (PSA), 46:60  
 (6;6)(q23;q27) in PLL, 48:184  
 (6;7)(q16;p15) in a thyroid carcinoma, 50:256  
 (6;7)(q23;p22) in vocal cord carcinoma, 44:215  
 (6;7)(q23;q22) in vocal cord carcinoma, 47:132  
 (6;7)(q27;q11.2) in human malignant melanoma (HMM), 48:240–241  
 (6;8)(p24;q21) in NHL, 47:78  
 (6;8)(q26-q27;q13) in angiofibroma, 45:168, 172  
 (6;8;21)(q21;q22;q22) in ANLL, 44:171, 173  
 (6;9) in MDS, 46:158  
 (6;9)(p23;q34) in M1 ANLL, 45:30, 47:213  
 (6;9)(p32;q34) in childhood ANLL, 45:139–140  
 (6;9;12)(q11;q12;q23) in esophageal carcinoma cell line, 45:105  
 (6;10)(10;18)(p11-p12;p14-p15p11;q11-q12) in angiofibroma, 45:168  
 (6;10)(p21.3;q22) in uterine leiomyoma, 47:181–182  
 (6;10;13;18)(q23;q21;q14;q21) in childhood erythroleukemia, 49:28  
 (6;11)(p11.2;p11.2) from radiation-induced tumors, 50:128  
 (6;11)(q11;q14) in benign uterine leiomyoma, 44:5  
 (6;11)(q31;q25) in benign uterine leiomyoma, 44:5  
 (6;12)(p11.2;p13) in peritoneal mesothelioma, 46:136  
 (6;12)(p21;p13) in breast cancer, 46:217, 224–225  
 (6;12)(p22;q23) in angioimmunoblastic lymphadenopathy (AILD), 50:18  
 (6;12)(q15;p13) in PLL, 45:153

- (6;13) in salivary gland pleomorphic adenoma (PSA), 46:59  
 (6;13)(6qter>6p21::13q12>13qter) in benign salivary gland pleomorphic adenoma, 44:256  
 (6;14)(p23;q21-22) in Sézary syndrome, 44:194  
 (6;14)(q21;q24) in metastatic ovarian adenocarcinoma, 45:223, 226; 48:250  
 (6;14)(q23;qter) in NHL, 47:78  
 (6;15) in murine plasmacytoma (MPC) involving c-myc and lambda light chain gene, 46:93-96  
 (6;15)(p12;q11) in MDS, 44:273  
 (6;15)(p23;q12) in angioimmunoblastic lymphadenopathy (AILD), 50:19  
 (6;15)(q16;q22) in esophageal carcinoma cell line, 45:105  
 (6;16)(p21;p13) in uterine leiomyoma, 49:54-55  
 (6;16)(q27;q12) after radiation therapy in Askin's tumor, 47:90, 92  
 (6;17)(p21;p12) in malignant mesothelioma (MM), 47:11, 26  
 (6;21)(q23;q24) in benign uterine leiomyoma, 44:5  
 (6;22)(p21;q11) masked Ph in CML, 47:223  
 (7;?) in bladder carcinoma, 49:145  
 (7;?)(p13;?) in mixed mesodermal tumor of ovary, 46:65, 67  
 (7;?)(p15;?) in Hodgkin's disease (HD), 50:7  
 (7;?)(p22;?) in Sézary syndrome, 45:235  
 (7;?)(q21;?) in NHL, 47:78  
 (7;?)(q32;?) in NHL, 47:78  
 (7;?)(q36;?) in ANLL, 44:173  
 (7;?)(q36;?) in NHL, 47:78  
 (7;7)(q32;q36) in T-cell ALL, 44:70, 72  
 (7;9) in bladder carcinoma, 49:145  
 (7;9)(p11-12;q11-13) in Sézary syndrome, 45:235  
 (7;9)(q35;q33) in T-cell ALL, 44:71, 72  
 (7;9)(q36;q22) in ANLL, 44:172, 173  
 (7;9;22) in a child with CML, 46:85  
 (7;9;22)(q22;q34;q11) variant in CML, 47:199  
 (7;10) in Hodgkin's disease (HD), 50:2  
 (7;11)(p12;q13) in malignant melanoma, 44:63, 64  
 (7;11)(p13;p15) in M4 ANLL, 45:30  
 (7;11)(q32;q13) from radiation-induced tumors, 50:128  
 (7;12)(q11;q21) in adenolymphoma, 46:37  
 (7;12)(q36;q13) in angiofibroma, 45:168  
 (7;12)(q36;q13) in parathyroid adenoma, 48:227  
 (7;13)(p15;q11) in adenoid cystic carcinoma, 44:159  
 (7;13)(p22;q12) in a thyroid adenoma, 50:255-256  
 (7;13)(q11;q34) in de novo MDS, 44:21  
 (7;13)(q36;q14) PHA-stimulated lymphocytes in family member of ATL patient, 49:160-161  
 (7;14)(p11;q11) in angioimmunoblastic lymphadenopathy (AILD), 50:22  
 (7;14)(p15;q11) TCR rearrangement in Sézary syndrome, 46:281-282  
 (7;14)(p21-p22;q21-q22) in angiofibroma, 45:168-169  
 (7;14)(q35;q12) in malignant mesothelioma (MM), 47:11, 28  
 (7;15)(p12;p11) in ANLL in relapse, 44:174  
 (7;15)(p14;q21) in uterine leiomyoma, 47:181  
 (7;15)(q22;q24) in SCC of the larynx, 44:211, 213  
 (7;16)(p11;p13) in ANLL in relapse, 44:174  
 (7;17)(p11;p11) in MDS and ANLL, 173-175, 178, 180-181  
 (7;17)(p11;q11) in Ph+ CML in CP, 47:201, 203, 210-211  
 (7;17)(q22;q11) growth factors (rhGM-CSF) in MDS, 48:171, 174-175  
 (7;17;20)(q35;q21;33;p11.2) in peripheral T-cell lymphoma (PTCL), 48:42  
 (7;22) in thyroid tumor, 44:127  
 (7;22)(q11;q13) in fibrosarcoma, 48:196  
 (8;?)(p23;?) in NHL, 47:78  
 (8;?)(q22;?) from radiation-induced tumors, 50:128  
 (8;8)(p23;q12) in uveal malignant melanoma, 45:251  
 (8;9) in salivary gland pleomorphic adenoma (PSA), 46:59  
 (8;9)(p23;p22-21) in lymphoid malignancies, 45:125, 128  
 (8;9)(q12;p21) in lymphoid malignancies, 45:125  
 (8;9)(q12;p22) in pleomorphic adenoma (PSA), 49:166  
 (8;9)(q13;p24) in ALL, 45:127-128  
 (8;9)(q22;p24) in ALL, 45:127-128  
 (8;9)(q22;q31) in radio- or chemotherapy treated sperm, 46:255  
 (8;9)(q24;p21-13) in lymphoid malignancies, 45:125, 128  
 (8;11) in follicular small cleaved cell lymphoma, 48:199-200  
 (8;11)(p21;q13) in follicular small cleaved cell lymphoma, 48:199-200  
 (8;11)(q11;p11) in medulloblastoma, 47:146

- (8;12)(q24;q24) in angioimmunoblastic lymphadenopathy (AILD), 50:19  
 (8;13) in salivary gland pleomorphic adenoma (PSA), 46:59  
 (8;13)(q22;q21) in uterine sarcoma, 44:32, 33  
 (8;13)(q23;q13) in childhood erythroleukemia, 49:28  
 (8;14) in B-cell lymphoid malignancies, 49:219  
 (8;14) in Burkitt-type PCL, 47:52  
 (8;14) in NHL, 47:73; 49:266; 50:55  
 (8;14) poor-risk subgroup in ALL, 49:8  
 (8;14)(q21;q23) in malignant mesothelioma (MM), 47:24  
 (8;14)(q22;q32) in acute megakaryoblastic leukemia (ANLL-M7), 48:122  
 (8;14)(q22;q32) in esophageal carcinoma cell line, 45:103, 106  
 (8;14)(q23;q32) in American Burkitt lymphoma stage II, 48:275  
 (8;14)(q24;q11) in T-cell ALL, 44:71-73; 49:3, 69, 71  
 (8;14)(q24;q11) MYC and TCRA in T-ALL, 49:6-7  
 (8;14)(q24;q24) in uterine leiomyosarcoma, 48:217, 220-222  
 (8;14)(q24;q32) in American Burkitt lymphoma stage II, 48:275-276  
 (8;14)(q24;q32) in B-ALL, 49:3  
 (8;14)(q24;q32) in Burkitt-type ALL, 44:69; 45:69, 155; 46:93; 49:69, 72  
 (8;14)(q24;q32) in NHL, 49:266  
 (8;14)(q24;q32) MYC and IGH in B-ALL, 49:6  
 (8;14)(q24.1;q11.2) from radiation-induced tumors, 50:128  
 (8;14)(q24.1;q11.2) in T-ALL, 49:71  
 (8;15;21)(q22;q21;q22) in ANLL, 44:171, 173  
 (8;16)(q22;q24) *mos* gene in AML and DS, 49:168  
 (8q16p) in breast cancer, 49:205-206, 208, 213  
 (8;17)(p11;q11) in malignant mesothelioma (MM), 47:11, 23  
 (8;17)(q11;q25) in Ph+ CML in CP, 47:202-204, 210  
 (8;18)(q11;q21) after radiation therapy in Askin's tumor, 47:90-92  
 (8;19;21)(q21;p13;q21-22) in ANLL, 44:171  
 (8;21) in AML 44:169, 172-177, 45:28, 30; 46:185-187; 49:10  
 (8;21) in de novo ANLL, 46:174  
 (8;21) with -Y in M2 ANLL, 46:170  
 (8;21)(q21;q11) in fibrosarcoma, 48:196  
 (8;21)(q22;q11) in secondary APL with loss of Ph at relapse, 47:41-45  
 (8;21)(q22;q22) appearance time of, 59:1490  
 (8;21)(q22;q22) in AL, 49:177-183  
 (8;21)(q22;q22) in de novo AML, 47:259, 262  
 (8;21)(q22;q22) in M1, M2, and M4 ANLL, 44:99, 103, 104, 169  
 (8;21)(q22;q22) in M2, 49:177-183  
 (8;21)(q22;q22) in M2 and M4 ANLL, 50:103, 105-107  
 (8;21)(q22;q22) in RAEB, 44:20, 18, 24  
 (8;21)(q23;q21) in essential thrombocythemia, 49:60  
 (8;21;5)(q22;q22;q31) in ANLL, 44:171  
 (8;22) in Burkitt lymphoma, 46:93  
 (8;22) poor-risk subgroup in ALL, 49:8  
 (8;22)(q22.1;q13.3) in M2 and M4 in ANLL, 50:103, 105-107  
 (8;22)(q24;q11) in B-ALL, 49:3  
 (8;22)(q24;q11) in Burkitt lymphoma, 49:72  
 (8;22)(q24;q11) in T-cell leukemia, 49:73  
 (8;22)(q24;q11) MYC and IGL in B-ALL, 49:6  
 (8;22)(q24.3;q11.2) from radiation-induced tumors, 50:128  
 (8;22)(q24;q32) in NHL, 49:266  
 (9;?) in NHL with del(7)(p14), 50:55  
 (9;?) in thyroid adenoma, 48:227  
 (9;?)(p13;?) in MDS and ANLL, 46:178  
 (9;?)(p23;?) in metastatic ovarian adenocarcinoma, 45:226  
 (9;?)(p23;?) in NHL, 47:78  
 (9;?)(q34;?) *c-myb* gene in T-cell malignancies, 48:231  
 (9;?)(q34;?) in angioimmunoblastic lymphadenopathy (AILD), 50:19  
 (9;10)(q22;q26) in SCC of the larynx, 44:211, 214  
 (9;10)(q32;q11.2) from radiation-induced tumors, 50:128  
 (9;10;15;19;22) in CML, 46:87  
 (9;11) in de novo ANLL, 46:174  
 (9;11)(p21;q14) in T-cell ALL, 44:71, 72  
 (9;11)(p22;q23) in acute monoblastic leukemia, 46:245  
 (9;11)(p22;q23) in AMoL, 45:9  
 (9;11)(p22;q23) in leukemia cells, 45:77, 46:6  
 (9;11)(p22;q23) in M4-M5 ANLL, 45:1, 8  
 (9;11)(p22;q23) transposition of *ets-1* in AL, 50:199, 201-202  
 (9;11)(q34;q21) in SCC of the larynx, 211, 214-215  
 (9;11;22)(q34;q13;q11) variant of CML, 47:199



- (9;12)(p11-13;p11-12) in ALL, 49:3  
(9;12)(p13-22;q13-15) in salivary gland pleomorphic adenoma (PSA), 44:156; 46:58  
(9;12)(p22;q11) alteration in RB1 gene in leukemia, 49:18  
(9;12)(q34;p12.3) from in vitro radioresistance, 50:132  
(9;12;22)(q34;q11/q13;q11) variant in CML, 47:199  
(9;12;22)(q34;q22;q11) in APL and in a case of CML BC with promyelocytic proliferation, 50:112  
(9;13)(p21;q13-21) in ALL, 45:125, 128  
  
(9;13)(q11;p11) in esophageal carcinoma cell line, 45:108  
(9;13)(q34;q12) in SCC of the larynx, 47:132  
(9;13)(q34;q12) in vocal cord carcinoma, 44:215  
(9;14;22)(q34;q11;q11) atypical Ph+ CML, 44:181, 182  
(9;15)(q13;q22) in childhood erythroleukemia, 49:28  
(9;15)(q13;q22) in M2 AML with promyelocytosis, 45:28  
(9;15)(q21;q21) in childhood erythroleukemia, 49:27  
(9;15)(q22;q25-q26) in angiofibroma, 45:168  
(9;15;22)(q31;q25;q12.2) in myxoid chondrosarcoma, 45:212  
(9q17q) in breast cancer, 49:205  
(9;18) in NHL with del(7)(p13), 50:55  
(9;19)(p11;q11) in nasopharyngeal carcinoma, 49:32  
(9;19)(p12;p13) in ANLL, 44:173  
(9;22) and disease-free survival in ALL, 49:9  
(9;22) and poor prognosis in ALL, 49:246  
(9;22) in childhood ALL, 49:4  
(9;22)(q22;q11) in myxoid chondrosarcoma, 45:212  
(9;22)(q34;q11) ABL and BCR in pre-B, C-ALL, 49:6  
(9;22)(q34;q11) alteration in RB1 gene in leukemia, 49:18  
(9;22)(q34;q11) bcr in Ph+ ALL, 47:29, 33-34  
(9;22)(q34;q11) DMS and +7 in BC of CML, 48:133-134  
(9;22)(q34;q11) in ALL, 49:3  
(9;22)(q34;q11) in CML, 45:28, 30; 45:69, 185, 193; 46:83, 85, 111, 46:170; 47:18, 56-57, 197, 203, 209, 219, 258-259; 48:75, 209, 211-212, 214  
  
(9;22)(q34;q11) in CML, effects of G-CSF on mitotic index (Ph+), 47:278  
(9;22)(q34;q11) in CML, effects of G-CSF on mitotic index (Ph-), 47:278  
(9;22)(q34;q11) in CP of CML, 47:261  
(9;22)(q34;q11) in Klinefelter syndrome with CML, 48:135  
(9;22)(q34;q11) in secondary APL with loss of Ph at relapse, 47:41-44  
(9;22)(q34;q11) late appearing Ph in ALL, 48:35-36  
(9;22)(q34;q11) Ph+ CML in a child, 44:277  
(9;22)(q34;q11) Ph+ CML in Hodgkin's disease (HD), 49:171-173  
(9;22)(q34;q11) Ph+ cells in unstimulated PB, 47:261  
(9;22)(q34;q11) Ph- cells in unstimulated PB after second BMT, 47:261  
(9;22;17)(q34;q11;p12) in a child with CML after BMT, 46:83-87  
(10;?)(p13-14;?) in Sézary syndrome, 45:235  
(10;?)(q26;?) in NHL, 47:78  
(10;10)(p15;q23) in endometrial adenocarcinoma, 47:157-158  
(10;11) in acute megakaryoblastic leukemia (ANLL-M7), 48:122  
(10;11)(p11;q12) in acute megakaryoblastic leukemia (ANLL-M7), 48:122  
(10;11)(p14;q21) in T-cell ALL, 44:71  
(10;11)(q11;p11) in Sézary syndrome, 45:235  
(10;11)(q22;p15) in uterine sarcoma, 44:32, 33  
(10;12)(q22;p13) from radiation-induced tumors, 50:128  
(10;13)(q24;q14) in angioimmunoblastic lymphadenopathy (AILD), 50:19  
(10;14)(p11;q11) in esophageal carcinoma cell line, 45:103  
(10;14)(q24;q11) in T-ALL, 49:3  
(10;14)(q24;q11) TCL3 and TCRD in T-ALL, 49:6-7  
(10;14;13)(q26;q22;q21.2) from radiation-induced tumors, 50:128  
(10;15)(p11;p11) in nasopharyngeal carcinoma, 49:32  
(10;15)(p15;q11.2) from radiation-induced tumors, 50:128  
(10;16) in mixed and myxoid liposarcoma, 48:104  
(10;16)(q11.2;p13.1) from radiation-induced tumors, 50:128  
(10;16)(q26;q12) variant in CML, 47:199-200, 207

- (10;17)(q22.1;p13) in uterine leiomyosarcoma, 44:32; 47:95, 98; 48:221
- (10;18)(p14-p15;q11-q12) in angiofibroma, 45:168
- (10;18;19)(p11;q11;p12) in a child with CML after BMT, 46:83-87
- (10;19)(q22;p13 or q13) in follicular thyroid adenoma, 48:227
- (11;?) in bladder carcinoma, 49:145
- (11;?)(p?;?) in ANLL, 44:173
- (11;?)(p11 or p13) in carcinoma of the cervix uteri, 44:230, 233
- (11;?)(p11.2;?) B cell growth factor (BCGF) and lymphoma cytogenetics, 48:111
- (11;?)(p12;?) in NHL, 47:78
- (11;?)(p14;?) in SCC of the larynx, 44:215
- (11;?)(p15;?) normal karyotype in leukemic cells before BMT, 47:255
- (11;?)(q;?) in fibrosarcoma, 48:196
- (11;?)(q13;?) in MDS and ANLL, 46:178
- (11;6;1)(q24;p25→q27;q31→q44) in esophageal carcinoma cell line, 45:105-106
- (11;12)(q21;q13) in salivary gland pleomorphic adenoma (PSA), 46:57
- (11;13) in salivary gland pleomorphic adenoma (PSA), 46:59
- (11;13)(p13;q14) in AMMoL, 45:261-262
- (11;13)(p15;q13-14) in synovial sarcoma, 50:277-278
- (11;13)(q14;q32) in angioimmunoblastic lymphadenopathy (AILD), 50:19
- (11;14) in B-cell lymphoid malignancies, 49:219
- (11;14) in B-CLL, 45:144-145, 151; 48:183, 187, 189-190
- (11;14) in CLL/PLL, 45:153; 48:184
- (11;14) in NHL, 47:73; 49:266
- (11;14) in PLL, 45:155
- (11;14)(p11;q11) in T-cell ALL, 44:70, 72
- (11;14)(p11;q13) in carcinoma of the cervix uteri, 44:230
- (11;14)(p12;q13) in childhood erythroleukemia, 49:28
- (11;14)(p13;q11) in T-cell ALL, 44:70, 72; 49:3
- (11;14)(p13;q11) in TCRA/D T-ALL, 49:6-7
- (11;14)(p13;q13) in T-cell ALL, 45:262
- (11;14)(p15;q11) TAL1 and TCRD in T-ALL, 49:6-7
- (11;14)(q12;—?32) in NHL, 47:78
- (11;14)(q13;q11) in T-ALL, 49:69
- (11;14)(q13;q32) in B-CLL, 48:183, 187, 189-190
- (11;14)(q13;q32) in NHL, 49:266
- (11;14)(q13;q32) in PCL and MM, 47:51
- (11;14)(q13;q32) in PLL, 48:184
- (11;14)(q22;q32) in diffuse large cell NHL, 50:54
- (11;16) in endometrial malignant mixed müllerian tumors (MMMT) 46:52
- (11;16)(q13;q24) in leiomyoma, 44:4
- (11;17)(q23;q25) in children with ANLL, 45:1, 5-6, 8
- (11;18)(q23;q21) in SCC of the larynx, 47:132
- (11;19) in ALL, 44:73
- (11;19)(p11, q13) in SCC of the larynx, 44:211, 214
- (11;19)(q21;p13) in adenolymphoma, 46:38
- (11;19)(q23;p13) in ALL, 49:3
- (11;19)(q23;p13) in AMoL, 45:77
- (11;19)(q23;p13) transposition of *ets-1* in AL, 50:199-204
- (11;20)(q13;q13) in SCC of the larynx, 44:211-212
- (11;21)(q23;q11.2) in MDS, 45:73, 79; 46:158
- (11;21)(q24;q11.2) in MDS at or near v-*ets* loci, 46:243-246, 249
- (11;22) in Ewing sarcoma, 47:1
- (11;22)(q23;q11) in Ewing sarcoma, 46:6; 47:89
- (11;22)(q23;q12) in Ewing sarcoma, 45:9
- (11;22)(q24;q12) after radiation therapy in Askin's tumor, 47:89-92
- (11;22)(q24;q12) in small cell osteosarcoma, 45:121-122
- (11;22)(q24;q12) primary skeletal Ewing sarcoma in DS, 47:61, 64-67
- (12;?) in salivary gland pleomorphic adenoma (PSA), 46:59
- (12;?)(p11;?) in MDS and ANLL, 46:178
- (12;?)(p12;?) in nasopharyngeal carcinoma, 49:32
- (12;?)(p13;?) in Hodgkin's disease (HD), 50:7
- (12;?)(p13;?) in MDS, 46:111
- (12;?)(p13;?) in MDS and ANLL, 46:178
- (12;?)(p13;?) in NHL, 47:78
- (12;?)(q13-15;?) in benign salivary gland pleomorphic adenoma, 44:253, 256
- (12;?)(q24;?) in NGL, 47:78
- (12;?;14)(p13q13;?:q24) in salivary gland pleomorphic adenoma (PSA), 46:60
- (12;12)(p13;q11) in erythroleukemia (EL), 50:91-92
- (12;12)(q13;q22) in endometrial adenocarcinoma, 46:43-45
- (12;12)(q14;q24) in uterine leiomyoma, 49:54-55

- (12;13)(p13;q14) in BP of CML, 47:219, 221-223
- (12p13q) in angioimmunoblastic lymphadenopathy (AILD), 50:19
- (12;14)(q13-15;q21-22) in benign uterine leiomyoma, 44:10
- (12;14)(q14-15;q23-24) in leiomyoma, 47:97
- (12;14)(q14-15;q23-24) in uterine leiomyoma, 44:32, 34; 45:63-66; 48:221-222
- (12;14)(q15;q24) in uterine leiomyoma, 47:183-184
- (12;14;14)(q22;q32;q23) with ring chromosomes in PCL, 47:49-50
- (12;15) in murine plasmacytoma (MPC) involving c-myc and lambda light chain gene, 46:93, 96
- (12;15)(p11;q11) in esophageal carcinoma cell line, 45:103
- (12;16) in liposarcoma, 47:1
- (12;16)(q13;p11) in myxoid liposarcoma, 47:186; 48:101-105
- (12;16)(q13.3;p11.2) in myxoid liposarcoma, 48:102-103, 105
- (12q16p) in breast cancer, 49:205
- (12;17)(p11;q11) in AML, 46:111
- (12;17)(p12-13;q12) in ALL, 49:3
- (12;17)(q13;p13) in B-CLL, 45:151
- (12;17)(q21;q11) in B-CLL, 45:151
- (12;18)(q13;q22) in ANLL, 44:173, 174
- (12;18)(q15;q23) in salivary gland pleomorphic adenoma (PSA), 46:60
- (12;20) in salivary gland pleomorphic adenoma (PSA), 46:60
- (12;21)(p13;p11) normal karyotype in leukemic cells before BMT, 47:254
- (12;21)(q13;q22) in leukemia secondary to MDS, 48:280
- (12;22) in acute megakaryoblastic leukemia (ANLL-M7), 48:119-122
- (12;22)(p13;q12) in acute megakaryoblastic leukemia (ANLL-M7), 48:119-122
- (13;?) in bladder carcinoma, 49:145
- (13;?)(p11.2;?) in nasopharyngeal carcinoma, 49:32
- (13;?)(13pter→13q34::?) in benign salivary gland pleomorphic adenoma, 44:256
- (13;?)(q34;?) in NHL, 47:78
- (13;13)(q31;q34) in CLL, 48:184
- (13;14) in ANLL, 45:194
- (13q14q) marker chromosomes in lung cancer cell line, 49:190-191
- (13;15) in atypical lymphoid leukemia, 45:194
- (13;15) in PLL, 45:194
- (13;15)(p11;q11) in adenocarcinoma of the prostate, 48:86
- (13;15)(p11;q11) in esophageal carcinoma cell line, 45:107, 112
- (13;15)(q11;p11) in esophageal carcinoma cell line, 45:106, 109
- (13;15)(q11;p12) in esophageal carcinoma cell line, 45:103
- (13;15)(q11;q26) after radiation therapy in Askin's tumor, 47:90, 92
- (13;16) in Hodgkin's disease (HD), 50:2
- (13;17)(cen;cen) in ANLL in relapse, 44:173
- (13;17)(q32;q21) in SCC of the larynx, 44:211, 214
- (13;18)(p11;p11) in human malignant melanoma (HMM), 48:240-241
- (13;19)(q14;q13.4) in peripheral T-cell lymphoma (PTCL), 48:42
- (13;20)(q14;q13) in SCC of the larynx, 44:211-212, 214-215
- (13;21)(p11;p11) in lymphoma, 44:279-280
- (13;21)(p11;q11) in esophageal carcinoma cell line, 45:108
- (13;22)(q32;q13) from radiation-induced tumors, 50:128
- (14;?)(q11;?) TCR rearrangement in Sézary syndrome, 46:281-282
- (14;?)(q32;?) normal karyotype in leukemic cells before BMT, 47:255
- (14;?)(q32;?) B cell growth factor (BCGF) and lymphoma cytogenetics, 48:111
- (14;?)(q32;?) in angioimmunoblastic lymphadenopathy (AILD), 50:19
- (14;?)(q32;?) in Hodgkin's disease (HD), 50:7
- (14;?)(q32;?) in NHL, 47:78
- (14;14)(p11;q11) in NHL, 47:78
- (14q14q) in carcinoma of the cervix uteri, 44:231
- (14;14)(q11.2;q32) in T-ALL, 44:47, 51, 52
- (14;15) in a SV40 virus-transformed tumorigenic human cell line, 50:231
- (14;15)(p11;p11) in RAEB-t, 44:23
- (14;15)(p11;q11) in adenocarcinoma of the prostate, 48:86
- (14;15)(q11;p11) in esophageal carcinoma cell line, 45:109
- (14q15q) in a SV40 virus-transformed tumorigenic human cell line, 50:239, 241-244
- (14;16)(p11;p11) alteration in the RB1 gene in leukemia, 49:18
- (14;16)(p13;q13) from radiation-induced tumors, 50:128



- (14;16)(q24;p13) in SCC of the larynx, 44:211
- (14;18) in B-cell lymphoid malignancies, 49:219
- (14;18) in B-CLL, 45:151
- (14;18) in diffuse large-cell lymphoma, 46:91
- (14;18) in follicular small cleaved cell lymphoma, 48:199–200
- (14;18) in NHL, 47:73; 49:266; 50:55
- (14;18)(q11.2;p13) recurrent marker in peripheral T-cell lymphoma (PTCL) 48:45
- (14;18)(q32;q21) B cell growth factor (BCGF) and lymphoma cytogenetics, 48:111, 113
- (14;18)(q32;q21) in follicular lymphoma, 45:127
- (14;18)(q32;q21) in follicular small cleaved cell lymphoma, 48:199–200
- (14;18)(q32;q21) in NHL, 47:78; 49:266
- (14;18)(q32;q21) B cell growth factor (BCGF) and lymphoma cytogenetics, 48:111
- (14;18)(q32;q34) B cell growth factor (BCGF) and lymphoma cytogenetics, 48:111
- (14;19) in CLL, 49:219, 221–222
- (14;19)(q32;q13) in B-cell lymphoma, 45:152
- (14;19)(q32.3;q13.1) in B-CLL, 49:219, 221–222
- (14;21) in APL, 45:194–195
- (14;21) in salivary gland pleomorphic adenoma (PSA), 46:58
- (14;21)(p11;q11) in esophageal carcinoma cell line, 45:105, 108
- (14q21q) in lung squamous cell carcinoma, 49:41–42, 45
- (14;22) in thyroid tumor, 44:127
- (14;22)(q13;p11) in breast cancer, 46:224
- (14;22)(q32;q11) in ALL, 49:3
- (14q22q) in breast cancer, 49:205
- (15;?)(p11;?) in NHL, 47:78
- (15;?)(q15;?) TCR rearrangement in Sézary syndrome, 46:281–282
- (15;?)(15qter→15q11::?) in benign salivary gland pleomorphic adenoma, 44:256
- (15q15q) in breast cancer, 49:205
- (15q15q) in lung squamous cell carcinoma, 49:40, 42
- (15;16) in murine plasmacytoma (MPC) involving c-myc and lambda light chain gene, 46:93–96
- (15;16)(q21;q13) in angioimmunoblastic lymphadenopathy (AILD), 50:19
- (15;17) in APL and in a case of CML BC with promyelocytic proliferation, 50:109–115
- (15;17) in de novo ANLL, 46:174, 180; 47:262
- (15;17) in M3 AL, 45:128
- (15;17) in M3 leukemia and in CML in promyelocytic blast crisis, 47:57
- (15;17)(q11.2;p11.2) from radiation-induced tumors, 50:128
- (15;17)(q22;q11–q12) in ANLL, 44:103, 104
- (15;17)(q22;q12) in APL, 45:28, 30
- (15;17)(q22;q12) in APL, 45:194
- (15;17)(q22;q12) in APL and in a case of CML BC with promyelocytic proliferation, 50:109–115
- (15;17)(q22;q12-21) in APL and in a case of CML BC with promyelocytic proliferation, 50:112
- (15;19)(q22;q24) in esophageal carcinoma cell line, 45:103
- (15;20)(p11;q11) in testicular and ovarian germ cell tumor cell lines (GCT) 50:67–69, 71–72
- (15;20)(q21;q13.3) in childhood erythroleukemia, 49:27
- (15;21)(q21-q22;q22) in ANLL, 44:99, 102–104
- (15;22)(p11;q11) in esophageal carcinoma cell line, 45:106, 109
- (15;22)(p11;q11) in nasopharyngeal carcinoma, 49:32
- (15;22)(q15;p13) from radiation-induced tumors, 50:128
- (15;22)(q21;q11) in malignant mesothelioma (MM), 47:11, 23
- (16;?)(p13;?) in uterine leiomyosarcoma, 48:217, 220–221
- (16;?)(q24;?) in acute megakaryoblastic leukemia (ANLL-M7), 48:122
- (16;?)(q24;?) in NHL, 47:78
- (16;?)(q24;?) in SCC of the larynx, 44:212, 215
- (16;?)(q24;?) in uterine leiomyosarcoma, 48:217, 220–221
- (16;16)(p13;q22) in myelomonocytic leukemia, 49:246
- (16p17q) in breast cancer, 49:205–206, 210, 213
- (16;19)(p11.2;p11) from radiation-induced tumors, 50:128
- (16;20)(p12;q13) in T-ALL, 49:241, 245–246
- (16;21)(p11;q22) in M1 ANLL, 47:139–140
- (16;21)(p11;q22) in M2 ANLL, 45:28
- (16;22)(p13;q11) atypical Ph+ CML, 44:181, 182

- (16;22)(q21;qter) in breast cancer, 49:206  
 (17;?) in bladder carcinoma, 49:145  
 (17;?)(p11;?) in RAEB-t, 44:23  
 (17;?)(p11-12;?) in MDS and ANLL, 46:173  
 (17;?)(p13;?) in nasopharyngeal carcinoma, 49:32  
 (17;?)(p13;?) in NHL, 47:78  
 (17;?)(q11;?) in adenolymphoma, 46:37  
 (17;?)(q23;?) in Hodgkin's disease (HD), 50:7  
 (17;?)(q24;?) in NHL, 47:78  
 (17;18)(q11.2q23) in AMMoL patient, 48:125-128  
 (17;19)(q23;p13) in ALL, 47:258  
 (17;20)(p13;p11.2) from radiation-induced tumors, 50:128  
 (17;22) in thyroid tumor, 44:127  
 (17;22)(p13;q12) atypical Ph+ CML, 44:181, 182  
 (18;?) in a SV40 virus-transformed tumorigenic human cell line, 50:231, 239  
 (18;?) polyploidization in colorectal adenocarcinoma, 44:110  
 (18;?)(p?;?) in a SV40 virus-transformed tumorigenic human cell line, 50:239, 242, 244  
 (18;?)(q;?) in essential thrombocythemia, 49:60  
 (18;?)(q23;?) in diffuse large cell NHL, 50:54  
 (18;19)(q21;q13) in SCC of the head and neck, 47:131-133  
 (18;22)(q12;q11) in meningioma, 45:239  
 (19;?)(p13;?) in NHL, 47:78  
 (19;?)(p13;?) in uterine leiomyosarcoma, 48:217, 220-221  
 (19;?)(p13.3?) in a SV40 virus-transformed tumorigenic human cell line, 50:243-244  
 (19;?)(p22;?) in SCC of the larynx, 44:211-212  
 (19;?)(q13;?) in Hodgkin's disease (HD), 50:7  
 (19;?)(q13;?) in NHL, 47:78  
 (19;?)(q35;?) normal karyotype in leukemic cells before BMT, 47:255  
 (19;t(19;?) structural rearrangement in colorectal adenocarcinoma, 44:112  
 (19;2;13)(q13;p13;q21) in esophageal carcinoma cell line, 45:108  
 (19;21)(q12;p13) from radiation-induced tumors, 50:128  
 (20;?) in thyroid tumor, 44:127  
 (20;?)(20pter→?20q13::?) in male breast cancer, 47:108  
 (20;?)(p12;?) in NHL, 47:78  
 (20;?)(q13;?) in subcutaneous leiomyosarcoma of the knee, 48:217, 220  
 (21;?) in a SV40 virus-transformed tumorigenic human cell line, 50:239  
 (21;?)(p11.2;?) in nasopharyngeal carcinoma, 49:32  
 (21;?)(q22;?) in AML, 46:111  
 (21;11)(q22.3;q23q14.2) rearranged and amplified *ets-1* in a lymphoma, 50:201  
 (21;21)(p11;q11) in CML, 45:193, 195  
 (21;21)(p11;q11) in essential thrombocytosis and myelofibrosis, 45:194-195  
 (21;21)(p11;q11) in t-MDS, ANLL and RAEB, 48:51  
 (21;21)(p11;q11) in t-MDS progressed to "frank" leukemia, 48:50  
 (21;22) in acute megakaryoblastic leukemia (ANLL-M7), 48:119-122  
 (21;22) in salivary gland pleomorphic adenoma (PSA), 46:58  
 (21;22)(p11;q11) in esophageal carcinoma cell line, 45:106, 109  
 (22;?)(p11;?) in nasopharyngeal carcinoma, 49:32  
 (22;?)(q12;?) in hepatocellular carcinoma, 45:259  
 (22;?)(q13;?) in acute megakaryoblastic leukemia (ANLL-M7), 48:122  
 (22;?)(q13;?) in NHL, 47:78  
 (22;22)(q11;q13) variant Ph translocation in CML, 47:199; 48:209-212, 214-215  
 (22;22)(q37;q11) variant Ph translocation in CML, 47:198-199  
 Trisomy  
 in AILD, 44:77, 50:15  
 in breast cancer, 46:217  
 in cervical cancers, 44:229  
 in CIS of testis, 46:75  
 in endometrial tumors, 46:41  
 in Hodgkin disease, 50:1  
 in large bowel cancer, 44:83, 107; 46:143  
 in lung tumors, 48:203  
 in lymphoma, 45:125; 47:73  
 in MDS, 46:173  
 in mesothelioma, 47:1  
 in renal cell carcinoma, 45:197  
 in T-ALL, 44:69  
 in thyroid adenomas, 44:217  
 in uterine tumors, 46:41  
 partial trisomies in tuberous sclerosis, 45:161  
 +3 and +12 in cold agglutinin disease, 46:89  
 +3 in male breast cancer, 47:107

- +4 in ANLL with hand-mirror cells, 45:265
- +4 in biphenotypic acute leukemia, 47:265
- +7 and +13 in colon polyps, 49:249
- +7 in atherosclerotic plaque, 47:273
- +7 in bladder cancer, 50:9
- +7 in gliomas, 47:141
- +7 in renal tumors, significance, 49:259
- +8 in ANLL, 45:1, 67
- +8 in CML, 47:197
- +8 in MDS, 44:15; 46:125, 157
- +12 in CLL, 45:143
- +12 in leiomyomas, 45:63
- +13 in ALL, 45:139
- +13 in MDS (RAEB), 48:179
- +14 in MDS, 49:113
- +19 in CML, 47:197
- +20 in liver tumor, 47:243
- +21 (transient) in MPD, 48:259
- Tuberous sclerosis
  - chromosomes in blood and skin cells and in angiofibromas, 45:161
  - cytogenetic studies, 45:161
  - 1, 3, 7, 10 and 15, 45:161
- Tumors
  - bladder, 46:129
  - brain (meningiomas), 45:41; 47:141
  - brain (pontine astrocytoma), 47:101
  - breast, 46:217
  - cervical (uterine), 44:229
  - endometrial, 46:41; 47:155
  - in Ewing sarcoma, 47:61
  - kidney, 45:197
  - large bowel, 44:107; 46:143
  - larynx, 44:209
  - leiomyosarcoma, 44:27; 47:89; 48:217
  - liver, 47:243
  - lung, 48:203
  - mesodermal, mixed; 44:27
  - myomas, 44:1; 45:63; 47:89; 47:179; 49:51
  - neurinomas, 45:55
  - ovary, 44:223; 45:49, 223; 46:65, 71, 115; 48:53, 243
  - salivary glands, 44:153; 46:35, 55
  - testis, 46:75; 48:1, 143
  - thyroid, 44:119, 217; 50:249
  - uterine, 44:1; 45:63; 46:41; 47:89, 155, 179; 48:217; 49:51
  - Wilms tumor, 45:35
- Uterus
  - cervical tumors, 44:229
  - chromosome 10 in endometrial cancer, 47:155
  - endometrial malignancies, 46:41; 47:155; 50:189
- leiomyoma, 44:1; 45:63; 47:89, 179; 49:51
- leiomyosarcoma, 44:27; 47:89; 48:217
- malignant mixed müllerian tumor, 46:41
- mesodermal tumor, 44:27
- sarcoma, 44:27
- SV40-transformed cell line and karyotype evolution, 50:231
- tumors, 44:1; 46:41; 47:155, 179; 49:51; 50:189
- Virus(es)
  - from vulvar neoplasia, 44:243
  - integration into 12q of human papillomavirus DNA, 44:243
  - papillomavirus (human, type 16), 44:243
- von Hippel-Lindau disease
  - chromosomes in kidney tumors, 49:125
  - kidney tumors in, 49:125
  - renal adenoma and, 49:125
  - renal cell carcinoma, 49:125
- Warthin's tumor
  - adenolymphomas, 46:35
  - chromosomes in, 46:35
  - of salivary gland, 46:35
- Wiedemann-Beckwith syndrome
  - Wilms tumor in, 45:35
- Wilms tumor
  - chromosomes, 45:35
  - in Wiedemann-Beckwith syndrome, 45:35
  - t(X;20) in, 45:35
- X chromosome
  - FRAXD at Xq27.2, 49:137
  - fra(X)(q28) in esophageal cancer, 45:269
  - in large bowel cancer, 44:107
  - loss in AILD, 44:77; 50:15
  - t(X;12) in lipoma, 49:235
  - two identical X chromosomes in breast cancer cell lines, 46:271
  - X-linked lymphoproliferative disease (XLP), 47:163
  - +X and -X in AILD, 50:15
  - X in M2 with t(8;21), 44:169
  - X in renal tumors, significance, 49:259
  - X in urothelial tumors and disease course, 50:97
- X-linked lymphoproliferative disease (XLP)
  - family with, 47:163
  - mapping of gene, 47:271
  - partial Xq25 deletion, 47:163
- X-ray; see Radiation exposure
- XYY male
  - with ALL, 49:225



## Y chromosome

- molecular studies of Y loss, 45:41
- XYY male with ALL, 49:225
- +Y in esophageal cancer, 45:269
- Y and thorotrast, 45:13
- Y in AILD, 50:15
- Y in MDS, 44:15; 46:157
- Y in meningiomas, 45:41
- Y in monocytic leukemia, 46:99
- Y in M2 with t(8;21), 44:169
- Y in M4, 44:99

- Y in neurinoma, 45:55

- Y in renal tumors, significance, 49:259

- Y in urothelial tumors and disease course, 50:97

- Y in Warthin's tumor, 46:35

## Yolk sac tumor

- chromosomes in, 44:223

- DNA studies in, 44:223

- metastatic, 44:223

- ovarian, 44:223

- testicular, 48:143

